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Abstract
Enterotoxigenic Bacteroides fragilis (ETBF), a human commensal and candidate
pathogen in colorectal cancer (CRC), is a potent initiator of IL-17-dependent colon
tumorigenesis in Min mice.
In Chapters 2 and 3, we examined the role of IL-17 and ETBF on the differ-
entiation of myeloid cells into myeloid-derived suppressor cells (MDSC) and tumor-
associated macrophages (TAM), which are known to promote tumorigenesis. The
myeloid compartment associated with ETBF-induced colon tumorigenesis in Min
mice was defined using flow cytometry and gene expression profiling. Cell sorted
immature myeloid cells were functionally assayed for inhibition of T cell prolifera-
tion in order to delineate MDSC populations. A comparison of ETBF infection to
that with other oncogenic bacteria (Fusobacterium nucleatum or pks+ E. coli) re-
vealed a specific, ETBF-associated colonic immune infiltrate. ETBF-triggered colon
tumorigenesis is associated with an IL-17-driven myeloid signature characterized by
subversion of steady-state myelopoiesis in favor of the generation of protumoral mono-
cytic (MO)-MDSC. Combined action of the Bacteroides fragilis enterotoxin bft and
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IL-17 on colonic epithelial cells promoted the differentiation of MO-MDSC, which
selectively upregulated Arg1 and Nos2, produced NO and suppressed T cell prolif-
eration. Evidence of a pathogenic inflammatory signature in humans colonized with
ETBF may allow for the identification of populations at risk for developing colon
cancer.
In Chapter 4, we describe targeting MDSC with the aim of suppressing tumori-
genesis. CXCR2, an inflammatory chemokine receptor expressed on neutrophils and
granulocytic (PMN)-MDSC, was a strong modifier of ETBF-Min tumorigenesis. In-
hibition of CXCR2, via genetic knockout or a synthetic peptide antagonist, pepducin,
significantly decreased recruitment of PMN-MDSC to the colon, increased numbers of
M1 macrophages and was anti-tumoral. Specific inhibitors of MDSC targeting CXC
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This year, colorectal cancer is expected to cause 49,190 deaths in the United
States. It is the third most common cancer, and ranks third in cancer-related deaths.
American men and women have a lifetime risk of developing colon cancer of 4.7%
and 4.4%, respectively.1 While global mortality is decreasing, especially in the West,
incidence rates are steadily climbings in developing nations in South America, Asia
and Eastern Europe.
Colorectal cancer is in essence a genetic disease. Initiation and progression fol-
low well-defined genetic and morphological pathways, with a long lead time of ten
to forty years between the initial transformation event and cancer diagnosis. Normal
colonic epithelium gives rise to small adenomas (polyps), which grow larger in size and
1
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eventually progress to carcinomas.2 Major genetic signaling pathways are impacted
sequentially, and their disruption allows progression to the next, more dysplastic
stage. The inactivation of tumor suppression genes involved in negative-feedback
mechanisms that attenuate proliferative signaling constitutes a gateway mutation,
and is followed by activation of oncogenes that allow for sustained proliferative sig-
naling.3 Key pathways in colon carcinogenesis are APC, Ras, PI3K/TP59/TGF-β,
and mutations in one or more associated driver genes are frequently encountered.4
Genetic risk factors have been identified, such as germline mutations in the DNA
repair genes MLH1, MSH2 or MSH6 in ‘Lynch Syndrome’, or the APC gene in ‘Fa-
milial Adenomatous Polyposis’. However, upwards of 90% of all colon cancers arise
sporadically in individuals with little to no genetic risk. Risk factors are diverse and
loosely associated, encompassing obesity, physical inactivity, smoking and high intake
of fat, alcohol or red meat.5 A longstanding hypothesis is that intestinal microbes
may contribute to colorectal cancer. This argument originated with insights into the
microbial load in the human gut, which contains 1013 bacteria, thus outnumbering
cells in the human body by 9 to 1. Interest in the contribution of the microbiome to
colon cancer initiation and progression dramatically increased after next-generation
sequencing enabled screening of bacterial species via 16S rRNA gene sequencing, shot-
gun metagenomic sequencing and other methods.6 Seminal work by Eckburg et al.
revealed an unimagined diversity within the human intestinal microbial flora, which
contains 500 to 1000 individual bacterial species.7,8 Furthermore, animal studies
2
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have provided clues to the association between microbiota and cancer. Such stud-
ies observed an amelioration of chemically-induced tumorigenesis in germ-free mice
or by a simple vivarium change, in which mice acquired a new microbiota.9 Now,
several models support the notion that specific bacterial pathogens, known as micro-
bial ‘drivers’, themselves constitute or recruit a consortium of microbes to initiate
colorectal cancer.10–12
The protective mucus layer lining the colon epithelium consists of two princi-
pal layers: a loose outer layer, which is densely inhabited by commensals and an
inner, gel-like layer, that acts as a physical barrier. Beneath lies the intestinal ep-
ithelial layer, which creates a cell barrier separating host tissue from the external
environment. Tight junctions and microvillar extensions on the apical surface of ep-
ithelial cells create an impermeable ‘brush border’, inhibiting microbial attachment
and invasion.13 Epithelial cells play a major role in maintaining mucosal immune
homeostasis, through microbial recognition, the ability to discriminate between com-
mensal and pathogenic bacteria as well as the regulation of immune cell functions of
the gut-associated lymphoid tissues. Notably, commensals can themselves modulate
intestinal epithelial-cell gene expression, i.e. inhibition of innate signaling pathways.14
Bacteria that enter the inner layer are rapidly cleared by the host immune system:
enterocytes release a multitude of inflammatory chemokines and cytokines leading to
the induction of an immune response, e.g. IL-8, a neutrophil chemoattractant and
CC chemokines MCP-1, MIP-1α, MIP-1β and RANTES, which attract monocytes,
3
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eosinophils and T cells.15 In inflammatory bowel disease, which if uncontrolled can
predispose an individual to developing colon cancer, bacterial invasion and persistence
in the inner mucus layer contribute to a state of chronic inflammation. Persistent
bacterial infection with or without symptoms with a disruption of the inner mucus
layer can result in pro-tumoral chronic inflammation.16 Thus, possible mechanisms
of bacteria-induced oncogenesis are considered to be:
1. chronic inflammation and
2. the production of oncogenic metabolites and toxins.10
To establish an association between exposure to a risk factor and subsequent dis-
ease, British epidemiologist Bradford-Hill established a set of criteria for causation.7
These criteria were originally devised and successfully applied to establish a causal
link between smoking and lung cancer. However, implementing them to support the
notion of a microbial genesis of colorectal cancer has of yet been unsuccessful. Two
key points as to why were highlighted in Eckburg’s work. First, many of human
commensal species are non-culturable. Second, two distinct communities exist: the
mucosa-associated and intraluminal microbiome.7,8 Further complication arises in
that infection with a tumorigenic bacterium may be short-lived and transient, and
may be no longer detectable at the time of cancer discovery.11
Three main models of host-microbe interactions exist to describe how microbiota
can contribute to tumor initiation and progression. The first involves the loss of
4
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the natural barrier function by colonic epithelial cells. This is the case in genetic or
auto-immune diseases and results in the translocation of normally apathogenic com-
mensal bacteria to submucosal layers, thus leading to an abnormal immune response
through innate pathogen associated molecular patterns (PAMP)-sensing. PAMPs
are conserved molecular patterns shared by microorganisms but not nonexistent in
mammalian cells, and can be recognized by invariant, germline-encoded receptors ex-
pressed on epithelial and cells of the innate immune system.17 The second model is
characterized by the prevalence of specific pathobionts, sometimes also referred to as
‘alpha-bugs’.12,18 In a permissive genetic or environmental background, the presence
of these pathogens alone is sufficient to promote tumorigenesis, in part through the
expression of oncogenic virulence factors. The third and final model involves the es-
tablishment of a dysbiotic microbial community within the colon, in which an atypical
mixture of normally apathogenic bacteria can promote tumorigenesis.10
Of the above models, there are significant efforts underway to better understand
how chronic pathobiont colonization can act as a carcinogen. The sum of these efforts
aim to identify culprit microbiota, which could allow for both early eradication and
abrogation of tumorigenesis altogether, or, at the least, identification of patients at
heightened risk of developing tumors. Chronic colonization with pathobionts such as
Enterotoxigenic Bacteroides fragilis ,19 pks+ E. coli20,21 and Fusobacterium nuclea-
tum22 may carry deleterious consequences, and is ultimately thought to foster tumor
initiation and promotion through the mechanisms described next. First, colonization
5
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leads to proliferation of the colonic epithelium through activation of proliferative sig-
naling pathways, such as Wnt, NF-κB or Stat3. Second, the ensuing inflammatory
response, mediated by both innate and adaptive effectors, can cause an inflammatory
milieu that is rich in genotoxic mediators such as reactive oxygen species and reactive
nitrogen species, resulting in DNA damage. In combination, hyperplasia and DNA
mutations predispose colon cancer.18
Chronic infection with pathobionts can follow the driver-passenger model already
eluded to.11 Specifically, this represents a stepwise model for colon cancer progression
following pathobiont infection. Initially, the normal epithelium becomes colonized
with pathobionts. The mechanisms of and risk factors for persistent colonization are
poorly understood and the course of infection differs from pathogen to pathogen.
However, persistent, if transient, chronic infection is necessary. Over the course of
infection epithelial cells become hyperproliferative and with changes in the local mi-
croenvironment — whether due to the inflammatory response or as a direct effect of
pathobiont colonization — the composition of the local microbiome shifts, with the
emergence of passenger bacteria. These can act as modifiers of the oncogenic process
depending on the bacterial species, and may accelerate or suppress tumorigenesis.
Once critical tumor suppressor pathways have been inactivated by mutations in the
underlying genes, adenoma formation occurs, eventually progressing to carcinomas.
At this stage, the driver bacteria may no longer be present, having been eliminated
by adaptive immune responses or through competitive growth disadvantage versus
6
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the new, modified passenger microbiome.
Forging a link between pathobiont colonization and tumorigenesis in humans faces
many challenges:
• Infection can be asymptomatic and relatively short-lived.
• Detection is complicated by whether bacteria are mucosa-associated or intralu-
minal, the former necessitating a biopsy for conclusive diagnosis, the latter able
to be detected in stool samples.
• Though many of the pathobionts identified to date are culturable, a large part of
microbial species within the gut are not, requiring implementation of alternative
methods for detection (sequencing, specific PCR).
• To achieve an oncogenic effect, many pathobionts require expression of onco-
genic virulence factors. Confirmation of their absence or presence is required.
• The absence of driver bacteria in the adenoma and carcinoma stages of colon
cancer, i.e. the window in which diagnosis is possible.
Taken together, these factors demonstrate that rather than rely on detection of the
causative pathobionts themselves, reliable surrogates of chronic colonization are re-
quired. A promising approach is to take advantage of host immune responses. Often,
these are long-lived and characteristic of infection with a specific pathogen. Early
inflammatory signals skew immune responses towards distinct effector types, such
7
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that different pathobionts are typically associated with different immune responses,
and quality is reproducible in case of multiple infections with the same species. The
observation that infection with a specific pathogen results in a specific immune re-
sponse has been termed, ‘immune signature’ and overcomes many of the challenges
associated with ascribing oncogenesis to a single pathobiont described earlier:
1. The interplay of pathogen-specific PAMPs and host pattern-recognition recep-
tors polarizes the effector response.
2. Since pathobiont infection is often chronic, immune responses are durable and
long-term, present even after driver bacteria no longer colonize the colon.
3. Characterization of immune responses is well-established and technically feasible
and could be performed in parallel to pathology diagnostics upon collection of
tissue, e.g. in endoscopy biopsies.
4. If major findings are reproducible in patients, immune signatures could serve as
a prognostic marker for oncogenesis and could assist clinical decision-making.
5. Specific immune signatures may facilitate characterization of certain pathogens
even if non-culturable and/or previously uncharacterized.
Immune signatures are already under development for use in cancer diagnostics




In microbially induced colorectal cancer, hypothetical scenarios could be as fol-
lows:
1. Recent infection with a pathobiont with evidence of malignancy-associated im-
mune signature could lead to antibiotic therapy and efforts to normalize the
microbiome and even provide passenger microbiota with tumor-suppressive ac-
tivity.
2. Detection of malignant immune signature in adenomas discovered during routine
screening colonoscopy could precipitate an aggressive screening regimen with
frequent check-ups.
3. Established colorectal cancer with specific immune signatures may prove to be
sensitive to immunotherapy and could guide therapeutic choices.
4. Epidemiological evidence of specific pathobiont-associated immune signature
and colorectal cancer could meet Bradford-Hill criteria and would lead to a
paradigm shift in the etiology of colorectal cancer and microbiota risk factors.
In this study, we present a novel mechanism: polarization of myeloid cells by a
putative oncogenic human symbiote, Enterotoxigenic Bacteroides fragilis (ETBF),
and the inflammatory cytokine IL-17, in Min (multiple intestinal neoplasia) mice.
Subsequently, myeloid cells, specifically myeloid derived suppressor cells (MDSC),
contribute to tumorigenesis. We identified a specific immune signature associated
with distal colon tumors that arise in ETBF-colonized mice which may, with further
9
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study, contribute to identifying patients at increased risk for developing colorectal
cancer.
The murine model of ETBF-induced IL-17-mediated colitis with ensuing tumori-
genesis is highly relevant to human biology and promises to unravel mechanisms of
microbially triggered human colon cancer.19 It provides several advantages:
1. ETBF is associated with acute colitis and colon cancer in humans.25
2. Th17 responses have been linked to poor outcome in human colorectal cancer.26
3. APC inactivation is a common mutation pattern in virtually all cases of colon
cancer.
4. The ETBF-Min model mimics the dominant prevalence of distal colon cancers
in humans.
5. The model also allows the role of IL-17 in promoting colon tumorigenesis to be
addressed, which remains poorly understood and controversial.27
1.2 Enterotoxigenic Bacteroides fragilis
Enterotoxigenic Bacteroides fragilis (ETBF) is a human commensal and candidate
pathogen in inflammation-induced human colorectal cancer. The genus Bacteroides
is numerically among the most prominent in the intestinal microbiome.28 The sub-
species B. fragilis are gram-negative anaerobes that colonize the entire length of the
10
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human colon and nonetheless grow in and benefit from nanomolar concentrations of
oxygen.29 B. fragilis has an unusually diverse gene repertoire of surface polysaccha-
rides (PS), and encodes eight distinct capsular polysaccharides (A through H), with
stable expression of a single type in colonized human hosts.30 These play a major
role in abscess formation,31 bacterial-mucosal contacts,32 mucosal immunity33 and in
modulating host-pathogen interactions.34
Interest in B. fragilis emerged in the 1970s when this subspecies was associated
with bloodstream infections35 and intra-abdominal abscesses.36 Notably, B. fragilis
was among the most common anaerobe isolated from clinical infections despite consti-
tuting less than 2% of the human microbiota.37 A decade later, Myers et al. reported
discovery of a B. fragilis strain capable of inducing inflammatory diarrhea in calves,
foals, lambs and pigs.38–41 Myers showed that inflammation was toxin-mediated by a
heat-labile metalloprotease termed B. fragilis toxin or ‘bft’.
In 1990, acknowledging the frequent involvement of zoonotic pathogens in human
enteric diseases, Myers and Sack chose to investigate ETBF in children and performed
a case-control study set in pediatric outpatient clinics in Whiteriver, Arizona. They
found that ETBF colonization was twice as likely in patients with diarrhea than
healthy controls (12% versus 6%).42 Another study conducted with 728 Swedish men
and women found a similar association between ETBF and diarrhea (27% in patients
with community-acquired diarrhea vs 12% in outpatient controls). In 2008, a study
by Sears and the International Centre for Diarrhoeal Disease Research expanded
11
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upon this research, and showed that ETBF is associated with inflammatory diarrhea,
characterized by the presence of fecal leukocytes as well as the inflammatory cytokines
IL-8 and TNF-alpha.43 Sears’ findings strengthened earlier research by Prindiville et
al., who showed an association of ETBF with inflammatory bowel disease44 and where
TNF is known to play a central role in the pathogenesis.45
The epidemiologic studies of ETBF in the 1990s and 2000s revealed that ETBF
was widely present in the general population, detectable in the gut of 20-35% of
children over one year of age and adults.46 In some, infection leads to acute in-
flammatory diarrhea, though in most cases chronic asymptomatic colonization was
observed. Researchers sought to combine these advancements in the understanding
of ETBF biology – from of chronic colonization, high levels of inflammatory cytokines
to emerging data on ETBF and inflammatory bowel disease – to establish a link to
the initiation and promotion of colorectal cancer. In 2006, Toprak et al. investigated
stool samples from colorectal cancer patients versus controls and found ETBF to be
significantly increased in specimens from colorectal cancer patients.47
Ongoing pre-clinical studies show that the EBTF toxin bft has potent oncogenic
activity. In cell culture, bft increases barrier permeability, chloride ion secretion and
leads to cleavage of E-cadherin, an integral cell-to-cell adhesion protein.48,49 Bft
binding to a putative cell surface receptor on colonic epithelial cells is thought to
mediate cleavage of E-cadherin resulting in release of β-catenin.50 Increased cytosolic
β-catenin triggers Wnt signaling and can promote cell growth through expression of
12
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c-Myc. Additional oncogenic effects include:
1. disruption of epithelial barriers,
2. activation of NF-κB signaling pathways and production of IL-8 as well as TNF-
alpha,51
3. upregulation of Cox2 resulting in increased levels of PGE252 and
4. induction of spermine polyamine metabolism with production of H2O2 that
results in apoptosis and DNA damage.53
The Bacteroides fragilis enterotoxin bft is both necessary and sufficient to cause
chronic inflammation in mice. Histology and immunohistochemistry revealed an in-
flammatory response characterized by hyperplasia, Stat3 activation, reactive oxygen
species production and DNA damage.54 ETBF expresses the toxin bft, while a closely
related species of B. fragilis, termed nontoxigenic B. fragilis (NTBF), does not.55
Studies comparing infection in mice demonstrated no differences in regards to colo-
nization. However, NTBF infection was asymptomatic, with little to no inflammation
and no significant induction of colon tumorigenesis. Importantly, NTBF does not en-
code the bft toxin. Asymptomatic infection was observed as well in mice inoculated
with genetically modified ETBF lacking the bft toxin (EBTF ∆bft), adding further
emphasis to the toxin’s potency as virulence factor.
In light of these observations, researchers have sough to demonstrate that ETBF
is a potent initiator of colon tumorigenesis in mice. Infection leads to uniform col-
13
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onization of the murine colon and results in persistent chronic inflammation with
oncogenic transformation. In C57/BL6 mice, mice develop IL-17A-dominant colitis
and the infection lasts over a year.55 In Min mice (APC∆716) infection results in
rapid tumorigenesis: microadenomas occur within days and polyposis present within
weeks.19
The Min strain is heterozygous for a mutant APC (adenomatous polyposis coli)
allele, encoding a protein truncated at amino acid residue 716 of 2845 (APC∆716).56
APC is a classic tumor suppressor gene; its role is to form a cytosolic complex re-
sponsible for binding and targeting β-catenin for proteosomal degradation. Min mice
typically develop multiple adenomas in the small intestine, but colon tumors in the
large intestine are exceedingly rare. However, upon single exposure with ETBF,
multiple colonic polyps, located predominantly in the distal colon, quickly become
detectable. Remarkably, the murine ETBF Min model mirrors several critical features
of human colorectal cancer including altered APC/β-catenin signaling, a predominant
distal localization of colon tumors and accurate reproduction of the pathogenic role
of overt IL-17.
Progression follows the same steps characteristic of human colorectal cancer: APC
loss of heterozygosity (LOH) is detected in a majority of early microadenomatous
lesions and virtually all colon tumors.56,57 LOH is considered a gatekeeper event in
early tumorigenesis as APC is a tumor suppressor gene and negative regulator of the
Wnt pathway. As part of a multi-protein ‘destruction complex’, APC binds to and
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phosphorylates β-catenin, leading to ubiquitin-mediated degradation.58 However,
as a consequence of APC LOH, cytoplasmic β-catenin translocates to the nucleus
with subsequent activation of transcription of Wnt target genes. It is unclear how
and whether ETBF contributes directly to APC LOH. Rapid onset DNA damage to
colon epithelial cells occurs in vivo in response to bft, as evident by activation of H2A
histone family, member X (H2AX).53 In vitro, the bft-induced polyamine catalyst
spermine oxidase can trigger production of reactive oxygen species, DNA damage,
and hyperplasia. Nonetheless, the timeline and mechanisms of LOH in Min mice —
thought to occur within days of challenge with ETBF — remains only insufficiently
understood.
Under steady state, cytoplasmic β-catenin is sequestered by E-cadherin, an intra-
cellular adhesion protein of the zonula adherens, and localized to cell-cell contacts.
However, bft disrupts cell-cell contacts, as shown by increased barrier permeability
with active secretion of chloride ions in colonic epithelial cell monolayers.59 ETBF’s
bft-mediated disruption of epithelial tight junctions in the colonic mucosa leads to
increased β-catenin signaling in the absence of functional APC.55 However, data does
not support direct cleavage of E-cadherin by ETBF, bft acts instead via a putative
epithelial cell-surface receptor, precipitating shedding of the E-cadherin extracellular
domain and presenilin-1/γ-secretase processing of the intracellular fragment.60 As a
result of enhanced nuclear β-catenin signaling, the oncogene c-Myc is upregulated,
thereby contributing to hyperproliferation.61 Presence of ETBF in the intestinal
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mucosa is accompanied by widespread and sustained Stat3 activation, in both ep-
ithelial as well as immune cells. Persistent Stat3 activation constitutes a pro-tumoral
signaling pathway, increasing tumor cell proliferation, survival and invasion while
suppressing anti-tumor immunity.62 In many cancers, persistent Stat3 activation is
mediated by the inflammatory pathways IL-6 and IL-17.63
Within a few days of ETBF infection, microadenomas become visible by mi-
croscopy in colons of Min mice. After 4 to 8 weeks, tumors are macroscopically
visible. In the subsequent weeks and prior to cancerous transformation of the numer-
ous colon polyps, euthanasia of the mice becomes necessary due to lethargy, likely
due to maldigestion secondary to bowel obstruction. Although tumorigenesis is nearly
always restricted to the distal colon (thus replicating the phenotype of polyp distribu-
tion in human Familial Adenomatous Polyposis patients), ETBF colonizes the entire
colon uniformly.64 Genetic knockout of Stat3 or of the Stat3-dependent cytokine
IL-17, can abrogate ETBF tumorigenesis in Min mice.19,65 Consistent with these ob-
servations, Housseau, Sears and Wu recently demonstrated that colonization of Min
mice with ETBF triggered IL-17-dependent colon tumorigenesis mediated in large




Infection with ETBF triggers a potent Th17 mediated inflammation and treatment
with αIL-17 antibody abrogates ETBF-induced tumor formation.19 IL-17 is required:
IL-17A−/− Min mice infected with EBTF are immune to tumorigenesis, and both
colom microadenomas as well as tumors are drastically reduced at 12 weeks post-
infection. Similarly, ETBF-infected IL-17RA−/− Min display lower tumor burden as
compared to IL-17RA-sufficient controls. An experiment in which bone marrow of IL-
17RA+/+ donors was transplanted into IL-17RA−/− Min showed comparable results:
reduction of microadenomas and absence of tumors in the colon of ETBF-colonized
mice.65
A study by Chae et al. confirmed the critical role of IL-17 in colon tumorigenesis.66
Herein, intestinal tumorigenesis was significantly reduced in IL-17−/− Min mice, and
microadenomas in the colon are virtually absent. Of importance is their finding
that IL-17−/− Min mice seem resistant to APC LOH, suggesting that a mechanism
downstream of IL-17 inflammation is necessary for APC LOH.
Although rare, healthy Min mice can develop sporadic microadenomas in the colon
associated with APC LOH, despite absence of ETBF. A possible explanation is that
other commensal bacteria induce IL-17 production in the colon, albeit at lower lev-
els. This hypothesis can be applied to a report by Dove et al., in which intestinal
tumorigenesis was assessed in germ-free wildtype and Min mice.67 Germ-free mice
trended to have less adenomas in their colon as compared to their conventional coun-
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terparts. In summary, against the backdrop of chronic inflammation, IL-17 is a potent
pro-tumoral cytokine when its levels are sustained.
Regulatory T cells (Treg) are recognized as a protective factor in Min mice tu-
morigenesis, and adoptive transfer of wildtype CD4+CD25+ cells to syngeneic Min
mice succeeds in inhibiting the development of 90% of intestinal tumors.68,69 Al-
though Treg are potent suppressors of Min tumorigenesis, Treg generated in germ-
free mice have impaired function,70 which may explain why the aforementioned study
with germ-free Min mice was inconclusive. These studies however, help explain the
baseline occurrence of microadenomas in Min mice, in which a subclinical infection
with commensals can elicit low level IL-17 response that is controlled by Treg. Impor-
tantly, while such a process is sufficient to induce microadenomas, adenomas seldomly
arise, suggesting that, in addition to APC LOH, further transformations must occur
in colonic epithelial cells for tumorigenesis to progress. More recently, the notion
that Treg are protective in the setting of colon carcinogenesis has been challenged
by findings of Geis et al., who showed that Treg promote the earliest stages of im-
mune carcinogenesis via enhancement of IL-17 production, while dampening IFN-γ
production.71
IL-17 can contribute to tumorigenesis via multiple mechanisms: activation of Stat3
and NF-κB as well as expression of VEGF and IL-6.72 Another is the G-CSF depen-
dent recruitment of immature myeloid cells (IMC):73 IL-17R knockout mice exhibit
tumor resistance, linked to lower levels of G-CSF and reduced recruitment of IMC to
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the tumor microenvironment. Recently, IL-17 was shown to orchestrate the selective
accumulation of CXCR2 myeloid-derived suppressor cells (MDSC) at inflammatory
sites and the TME via promotion of CXCR2 ligand expression by stressed epithelial
and tumor cells. He et al. found that tumor growth inhibition in IL-17R-deficient
mice or via IL-17 neutralizing antibody treatment was due to reduced MDSC infil-
tration and increased numbers of intra-tumoral cytotoxic CD8 T cells. In a model of
carcinogen-induced de novo tumorigenesis, Wang et al. showed that IL-17 activated
STAT3 through IL-6, and an IL-6-STAT3-dependent pathway regulated the expres-
sion of several inflammatory mediators (e.g. CXCL1, S100A8, S100A9, Cox2 and
IL-1β).74 These cytokines have in common the ability to act specifically on immature
myeloid cells (IMC) and may contribute to shifting steady-state myelopoiesis towards
the generation of MDSC.75
Together with T reg, MDSC mobilization to tissues in response to inflammatory
stimuli represents a homeostatic mechanism designed to limit collateral damage.76
Cancer, via its associated inflammatory microenvironment and cytokine milieu, can
alter the steady-state maturation and differentiation of mobilized IMC, including
monocytes (MO), macrophages (MΦ), dendritic cells (DC) and polymorphonuclear
(PMN) cells. This can result in the generation of procarcinogenic myeloid cell popu-
lations, the most important of which are MDSC. In the context of ETBF infection,
immature myeloid cells (IMC) are recruited to the inflamed colon lamina propria,
persist in the tissue, and accumulate in tumors where — as a result of the surround-
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ing microenvironment and tumor-secreted factors — differentiate to MDSC as well
as tumor-associated macrophages (TAM).
1.4 Myeloid-derived suppressor cells
Myeloid derived suppressor cells originate in the bone marrow from hematopoi-
etic stem cells, specifically the common myeloid progenitor cell. Under homeostatic
conditions, the bone marrow generates progenitor cells that go on to differentiate
into macrophages, dendritic cells and neutrophils in the periphery. In cancer and
other chronic pathologic conditions, these cells fail to differentiate and remain in an
immature state, and are thus referred to as IMC. Hallmarks of MDSC are as follows:
1. Myeloid origin,
2. Immature state and
3. Immune suppressive.
Despite being phenotypically and functionally heterogeneous, MDSC are derived
from a common myeloid lineage and share a capacity for immune modulation. The
two main subsets of MDSC are defined as granulocytic (PMN) and monocytic (MO)
MDSC. In contrast to IMC, which are not immunosuppressive at steady state, MDSC
respond to inflammatory cytokines such as IFN-γ, IL-4 and IL-13, as well as various
danger signals or TLR ligands. Their activation triggers the deployment of immuno-
suppressive effector functions, including nitric oxide (NO), reactive oxygen species
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(ROS), and arginase 1 (Arg1), a potent metabolic enzyme which acts as a T cell im-
munosuppressant by depleting arginine in the local milieu. Several transcription fac-
tors critical to MDSC function have been identified, the most prominent of which are
proteins of the STAT family as well as NF-κB.77 Nonetheless, available data suggest
the existence of other, as yet unrecognized, signaling pathways and transcriptional
regulators critical to the immunosuppressive activity of MDSC.78
Historically, these cells were termed ‘null cells’ due to lack of expression of CD3,
CD56, CD19 and CD13, or designated natural suppressors, in recognition of their
capacity to inhibit lymphocyte numbers and T lymphocyte activity.79 In mice, the
lack of specific markers meant the defining characteristic of these cells was their
suppressive function. Null cells drew interest as they were discovered in mice to
deplete lymphoid populations,80 and to occur in close association with tumors81.82
Researchers soon recognized several factors that could exacerbate myeloid suppressor
cell numbers:
1. the abnormal induction of hematopoiesis, such as by injection of cyclophos-
phamide,83
2. co-culture with tumor secretions84 and
3. the exogeneous supply of GM-CSF85 or G-CSF.86
Importantly, reduction of NS cell numbers, achieved through administration of IFN-
γ and TNF-α,81 could diminish tumor recurrence and metastasis. Similarly, tumor
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growth could be inhibited by antibody-mediated depletion of granulocytes.82
In the mid 1990s, lineage-negative myeloid populations were first documented87,88
and an inverse relationship between T cell function and MDSC was uncovered in
cancer patients.89 Ectopic production of GM-CSF in patients with head and neck
carcinoma was associated with increased myeloid cell suppressive activity, recurrence
and metastasis.89 Host tumor burden often strongly correlated with the increased
number of suppressive cells in circulation9091 and solid tumor resection could success-
fully reduce myeloid cell numbers, thus restoring immunity.92 In a murine mammary
adenocarcinoma model, reduction of suppressor cells achieved objective responses,
decreased tumor burden and led to improved survival.93 Unlike in mouse models,
where tumor burden could be reduced by manipulation of myeloid cell numbers, few
clinical studies have shown improved overall survival in response to targeting myeloid
suppressor cells.94 We now know that the number of circulation MDSC has the like-
ness of a biomarker and can predict: disease progression and poor prognosis,94 tumor
angiogenesis95 and osteoporosis.96,97 A better understanding of the biology of these
suppressor cells will be necessary to produce therapeutic strategies that will translate
into improved clinical outcomes.
There are two distinct subsets of myeloid-derived suppressor cells: (1) monocytic
(MO) and (2) granulocytic or polynuclear (PMN). MO-MDSC are usually charac-
terized by high expression of Arg1 and production of nitric oxide as well as of sup-
pressive cytokines, i.e. IL-10 and TGF-β. Like monocytes, they express surface
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markers such as F4/80, CD115, 7/4 (Ly6B) and CD192 (CCR2). They suppress
in an antigen-unspecific fashion and can give rise to tumor associated macrophages
through Hif1-α signaling triggered by hypoxia in the tumor bed.98 PMN-MDSC are
more-closely associated with the production of reactive oxyges species, such as O2−,
H2O2 and peroxynitrates (PNT). In contrast to the MO effector products, these are
short-ranged and short-lived, such that PMN-MDSC require cell-to-cell contact and
suppresses antigen-specific CD8+ T cell in an antigen specific manner.99
In mice, MDSC were initially characterized as CD11b+ Gr-1+ cells, while lacking
markers typical of terminally differentiated macrophages and dendritic cells.100,101
The two distinct subsets can be separated by differential expression of the Ly6C and
Ly6G markers:102
MO-MDSC CD11b+ LyC6high Ly6G−
PMN-MDSC CD11b+ Ly6Clow Ly6G+
Human MDSC characterization remains controversial due to their heterogeneity.
MDSC subsets have been identified on the basis of CD14 (MO) or CD15 (PMN)
and CD33 co-expression within the HLA-DR- and lineage- compartment (i.e. CD3−,
CD19−, CD56−, CD13− with CD33 as an exception).103 Since their discovery, the
nature of MDSC has been open to question: Debate arises on if they are a distinct,
evolutionary population or if they represent a transient state, arrested in development
and prevented from progressing to mature innate effector cells, such as neutrophils
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and macrophages104? Notably, the phenotype of MO and PMN-MDSC, based on
the expression of Ly6C and Ly6G is the same of inflammatory monocytes and of
neutrophils, respectively.105,106 As Youn et al. pointedly state:
“MDSC are not simply the result of myeloid precursor cells expanding un-
der pathological conditions. MDSC is a functional definition of immature
myeloid cells that have acquired potent immune suppressive activity and
other non-immunological functions.”104
MDSC arise during long-term chronic pathological conditions, such as chronic in-
flammation, infection, or cancer. In contrast, acute bacterial infections do not result
in the expansion of MDSC. When MDSC enter the tumor microenviroment, they un-
dergo differentiation to tumor-associated macrophages (TAM). Narita et al. demon-
strated that spleen-derived MDSC differentiated into suppressor macrophages under
the influence of tumor cell-derived factors obtained from CMC-1 carcinoma culture
supernatant, while concomitantly increasing their inhibitor activity.107 These find-
ings were confirmed by adoptive transfer of MDSC to tumor-bearing mice, in which
differentiation into TAM with potent immunosuppressive activity was observed.108
The concern regarding nomenclature was addressed in a 2007 letter to The Journal of
Cancer Research, in which leading experts in the field called for the universal adoption
of the MDSC term, making the following argument:
“In the literature, these cells have been called immature myeloid cells or
myeloid suppressor cells (MSC). Although both of these names reflect the
biology of cells, neither term is entirely accurate. The name immature
myeloid cell implies that these cells are normal myeloid precursors. [...]
The name MSC implies that these cells include populations of mature
myeloid cells, such as macrophages or dendritic cells, capable of displaying
some immunosuppressive features under certain circumstances.”109
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Tumor-secreted factors affecting MDSCmaturation include VEGFA,101 GM-CSF,110
FMS,111 Kit ligand,112 G-CSF113 and M-CSF.114 Many of these factors can act on two
levels, the first is cellular accumulation and expansion, the second is activation. These
two processes are interconnected and regulated by overlapping transcription factors:
Stat3, IRF8, CEBP-β, Stat1, Stat6 and NfKB.77 Stat3 plays a major role in MDSC
biology, including: prevention of apoptosis,62 promotion of proliferation115 and upreg-
ulation of the pro-inflammatory proteins S100A8 and S100A9. These, in turn, inhibit
DC differentiation,116 promote recruitment of MDSC to tumor sites, boost their accu-
mulation and enhance their suppressive activity.117 NADPH oxidase, a multi-protein
complex consisting of the subunits p47phox and gp91phox, are also downstream of
Stat3, and its activation results in increasing ROS levels, which translates to enhanced
inhibitory activity of MDSC.118 Signaling through Stat1 increases iNOS expression108
while Stat6 controls Arg1119 and TGF-β expression,120 all of which are critical to
MDSC-mediated immune suppression. TLR family proteins, which signal through
a set of common adapters, MyD88 and TRIF, and subsequent activation and nu-
clear translocation of the Nf-κB transcription factor, are important for mobilization
of MDSC to tumor sites.121
Another level of regulation occurs through cytokines released by activated T cells,
such as IFN-γ, IL-4, IL-10 and IL-13.122 These act in concert with tumor-derived
pro-inflammatory factors, such as IL-1-β, IL-6, S100A8 and S100A9 to divert the
maturation of immature myeloid cells first to MDSC then to immunosuppressive
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TAM.123 Lastly, chemoattractants play a crucial role in the recruitment of immature
myeloid cells to the TME. CCL2 and CCL12 can bind to CCR2 expressed on MO-
MDSC as well as on macrophages, while members of the CXCL chemokine ligand
family (1, 5, 6, 8, 12) can bind to receptors such as CXCR2 on the surface of PMN-
MDSC.124
The main pro-tumoral mechanisms employed by MDSC are as follows:




Enhancing tumor cell survival is most potently achieved by suppressing anti-tumor
immune responses and by inactivation of apoptosis. Four principal immunomodula-
tory mechanisms have been described, which are mediated by specific key proteins:
Nox2 (NADPH oxidase), Arg1 and Nos2. The first involves the depletion of nutri-
ents required by lymphocytes to sustain effector functions. Arg1 reduces interstitial
levels of L-arginine.125 Amino acids essential to the metabolism of effector T cells
L-cysteine126 and tryptophan are consumed or sequestered from local inflammatory
sites through transporters or enzymes such as Xc- and indoleamine 2,3-dioxygenase.
The result is a downregulation of the T cell receptor due to loss of the TCR-ζ chain,
and proliferative arrest of T cells.
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The second is the generation of oxidative stress. Nox2 or Cybb, a subunit of
NADPH oxidase, can catalyze the production of ROS. Combined and cooperative
action of NADPH, Arg1 and Nos2 can lead to the generation of reactive nitrogen
species such as oxygen radicals (O−2 ), hydrogen peroxide (H2O2) and peroxynitrite
(ONOO). The result is a loss of the TCR-ζ chain,127 nitration or nitrosylation of TCR,
CD8 or CD3, resulting in desensitization and reduced TCR signaling.128 Nitrosylation
also interferes with IL-2 receptor signaling.129
A third mechanism of inhibition of T cell responses employed by MDSC is interfer-
ence with T cell migration, trafficking and viability. The metalloproteinase ADAM67,
which is expressed by MDSC, can cleave CD62L on naive T cells, thus preventing their
migration to draining lymph nodes and the transition to effector state. Galectin 9,
an S-type-lectin which is expressed by MDSC, can bind to the immune checkpoint
TIM3 on murine T cells and induce apoptosis,130 though there is controversy as to
whether this interaction translates in humans.131 Membrane-bound TGF-β binds to
inhibitory NK cell receptors (NKp30).132
Lastly, MDSC secrete inhibitory cytokines such as IL-10 and TFG-β, leading to
suppression through fostering de novo Treg development and expanding Treg recruit-
ment.133 High levels of IL-10 also act on tumoricidal M1 macrophages, which are
skewed to the protumoral M2 phenotype leading to reduction of IL-12 levels and thus




Commensals lining the gut epithelium interact with innate receptors and impact
the development, basal activation, maintenance and regulation of local inflamma-
tion and immunity.135 This intricate, usually symbiotic relationship can be disrupted
by changes in the local microbial community (termed dysbiosis), which alters the
predominant species (bloom of specific taxa) and modifies the composition of the mi-
crobial community (changes in diversity).136 Dysbiosis has been directly associated
with colon cancer in human metagenomic studies.22,137,138 Furthermore, novel evi-
dence compellingly suggests that the gut microbiota exert profound influence on the
response to cancer immunotherapy and chemotherapy by affecting the differentiation
of myeloid cells.139 As such, it is highly likely that the reverse is true, and pathobionts
and dysbiosis can directly influence myeloid cells to advance initiation and promotion
of colorectal cancer.
Principal inflammation-induced oncogenic mechanisms include:
1. Direct mutagenesis through DNA damage secondary to reactive oxygen and
reactive nitrogen species, i.e. as shown by p53 mutations through oxidative
damage in colitis-associated cancer.140
2. Inactivation of mismatch repair genes, resulting in enhanced inflammation-




3. Production of growth factors that can confer a stem cell-like phenotype upon
epithelial cells, stimulating proliferation and resulting in hyperplasia, the most
important of which are : Stat3, NF-κB and TNF-α. Stat3 is associated with
stem cell reprogramming and renewal.142 NF-κB increases Wnt/β-catenin sig-
naling in colonic crypts.143 Similarly, macrophage-derived TNF-α has been
shown to promote Wnt signaling.144
Notably, many of these oncogenic transcription factors can be switched on by bac-
terial pattern-associated molecular patterns binding to host cells via cognate toll like
receptors.145 In turn, innate responders, such as myeloid cells and macrophages, can
secrete pro-tumoral cytokines that are prominently involved in tumor initiation and
progression. Early production of IL-6 and IL-11 originating from MDSC potentily in-
duced Stat3.146 In colitis-associated cancer (CAC), MDSC contributed to early stage
hyperplasia and inhibition of apoptosis in epithelial cells.147 Disruption of NF-κB
signaling in a mouse model of CAC blocked production of IL-6, thus reducing tu-
morigenesis.148 There is strong evidence that myeloid derived early pro-inflammatory
factors IL-6, IL-11, TNF-α149 and IL-1-β150 play a leading role in tumorigenesis. TAM
secreted IL-23 is another potent inflammatory cytokine, driving IL-17 and IL-22 pro-
duction by Th17 T cells. TAM-derived IL-23 is upregulated by Stat3, PGE2, ATP
and lactic acid production by shifting the reciprocally regulated pro-tumoral IL-23/
anti-tumoral IL-12 axis towards the former.151
In light of this data, we hypothesized that ETBF inflammation and the ensuing
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high-levels of IL-17 production19152153 act to disrupt normal myelopoiesis and result
in the accumulation of procarcinogenic MDSC in the TME. Our findings suggest
that in contrast to the non-colitogenic Fusobacterium nucleatum,22 or the T cell-
independent pks+ Escherichia coli ,20 ETBF oncogenesis requires the coordinated
action of its toxin, bft and an IL-17-driven inflammatory response to orchestrate the
recruitment of myeloid cells to the TME, as well as their differentiation and activation
into immunosuppressive MDSC, specifically, iNOShi MO-MDSC. We propose that
ETBF-triggered colon tumorigenesis is characterized by a specific immune signature
combining IL-17-driven colitis and altered myeloid differentiation into MO-MDSC.
Taken together, myeloid cells can be differentially programmed by cues originating
from the interplay between host and microbiome. These can be anti-tumoral or
pro-tumoral, depending on the microbial community, and the presence of specific
driver bacteria. Understanding the mechanisms between colonization with a specific
pathobiont, the mobilization and activation of MDSC and how these events are linked
to tumor initiation and progression will contribute to discovering the aetiology of
human colorectal cancer, and may give rise to new tools and therapies for colon




2.1 ETBF specifically promotes the accu-
mulation of immature monocytic cells
in colon tumors of Min mice
CD11b+ myeloid cells accumulated progressively over time in the distal colon of
ETBF Min mice and at 3 months made up 77.6 ± 5.4% (mean ± SEM, n=3 ex-
periments) of the tumor-infiltrating CD45+ leukocytes (Figure 2.1A) or 6.5 ± 1.5%
of all viable epithelial and hematopoietic cells. Thus, myeloid cells constituted the
overwhelming majority of hematopoietic cells that infiltrated colon tumors in Min
mice after 3 months of ETBF colonization. Among CD45+ leukocytes, three main
groups of CD11b+ myeloid cells comprised the ETBF colon TME: macrophages (MΦ)
31
CHAPTER 2. RESULTS
(Gr-1-, 25 ± 7.1%), monocytic (MO)-IMC (Gr-1low or Ly6ChiLy6G-, 11.8 ± 1.7%)
and granulocytic (PMN)-IMC (Gr-1hi or Ly6ClowLy6G+, 45.3 ± 7.9%) populations
(all mean ± SEM, n=3 experiments, representative flow cytometry plots are shown
in Figure 2.1B). CD4+ T cells and γδ+ T cells, the predominant sources of protu-
moral IL-1719,65 , made up only 1% and 0.1% of all CD45+ cells, respectively (Figure
2.1). When comparing myeloid cell infiltration in the distal colon between C57BL/6
wildtype (WT) and Min mice, we noticed that IMC were readily detectable in both
strains at 1 week following infection (Figure 2.1C). However, with persistent ETBF
colonization, IMC – especially PMN-IMC – accumulated in higher numbers in Min
mice, while in WT, myeloid populations regressed by 8 weeks. To assess whether these
observed differences were due to differential Apc function in Min versus WT mice,
we addressed whether the Apc mutation affected the hematopoietic cell compart-
ment in Min mice. For this purpose, lethally irradiated Min mice were reconstituted
with WT or Min bone marrow (BM), challenged with ETBF and assessed for tu-
mor numbers. As displayed in Figure 6.1, we found no significant difference between
WT and Min BM-engrafted recipient Min mice, implying that Apc heterozygosity in
the hematopoietic compartment does not impact tumorigenesis. This result suggests
that the local myeloid environment is shaped by Apc loss of heterozygosity (LOH) in
colonic epithelial cells (CEC) in conjunction with ETBF colonization of the colon.
We previously demonstrated that ETBF stably colonizes the colon, but not the
small intestine (SI), yielding markedly induced colon tumorigenesis in Min mice, lo-
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Figure 2.1: Myeloid cells are the predominant leukocytic population infiltrating ETBF-
induced colon tumors in Min mice
A, Myeloid cells from enzymatically digested grossly normal distal colon tissue (weeks 2, 8 and 12 after ETBF colo-
nization) and distal colon tumors (12 weeks post ETBF) were analyzed by CD45/CD11b staining and flow cytometry.
Results are expressed as percent (%) of CD11b+ cells among viable CD45+ leukocytes. Aggregate data of n=7 inde-
pendent experiments with pooled colon or tumors samples from 3-4 mice/experiment.
B, Flow cytometry of ETBF-triggered colon tumors in Min mice. Percent CD45+ cells are indicated. Representative
plots of n=3 or more experiments with 3-4 mice/experiment.
C, Proportion of Ly6ChiLy6G- monocytic immature myeloid cells (MO-IMC) (white bars) and Ly6CloLy6G+ granu-
locytic (PMN)-IMC (black bars) as percent of CD11b+ isolated from distal colon of WT (top) or Min (bottom) mice
at the time points indicated. Of note, IMC in distal colon tissue of sham Min mice were below the limit of detection.
Aggregate data of n=4 independent experiments with pooled colon samples from 3 mice/group.
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calized predominantly to the distal colon (Figure 6.1).19 In contrast, SI tumori-
genesis, a characteristic of parental Min mice, is unchanged upon ETBF coloniza-
tion.19 We examined the myeloid compartment present in SI (ETBF-independent)
and colon (ETBF-dependent) tumors as well as normal adjacent tissue by flow cytom-
etry and microscopic analysis. We distinguished MΦ (CD11b+F4/80+MHC-II+Gr-
1-CD11c-/lowSSCint), dendritic cells (DC, CD11chiMHC-IIhiSSClow), mast cells (MC,
CD11b-FcϵRI+CD117(c-kit)+), MO-IMC (CD11b+Gr-1hiF4/80hiCD11c-/lowMHC-II-/+SSChi)
and PMN-IMC (CD11b+Gr-1hiF4/80-CD11c-MHC-II-SSChi) (Figure 2.2A–C). FSC/SSC
analysis (Figure 2.2B) and Wright-Giemsa staining performed on PMN-IMC and MO-
IMC sorted from ETBF-induced colon tumors confirmed their distinct morphologies
(Figure 2.2C). Notably, although developing concomitantly in ETBF-colonized Min
mice,19 the SI- and colon tumor-associated tumor microenvironment (TME) had dis-
tinct myeloid infiltrates (Figure 2.2D). MC were present in SI tumors but sparse in
colon tumors (3.5 ± 2.3% in SI versus 0.3 ± 0.2% in colon, p<0.05, mean ± SEM) and
PMN-IMC were significantly more common in colon tumors than in SI tumors (8.9 ±
3.9% in colon versus 1.2 ± 0.6% in SI, p<0.05, mean ± SEM). The normal tissue ad-
jacent to colon tumors was characterized by a robust population of CD11chiMHC-IIhi
DC (29.7% of viable cells in normal vs. 5.8% in ETBF tumors, Figure 2.2A).
Subsequent comparison of the myeloid environment in colon tumors of ETBF-
colonized versus sham Min mice provided evidence of altered myeloid differentiation
in direct response to ETBF colonization (Figures 2.3A,B). Both the rare, sporadically-
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Figure 2.2: Characterization of the myeloid compartment in ETBF-colonized Min mice
A, Flow cytometry of distal colon tumors (top) as well as adjacent grossly normal colon tissue (bottom) isolated from 3
month ETBF-colonized Min mice. CD11bhiGr-1loMHC-IIloF4/80-/low MO-IMC; CD11b+Gr-1hiMHC-IIloF4/80-/low
PMN-IMC; CD11b-FcRI+CD117+ mast cells (MC); CD11b+Gr-1-F4/80+ macrophages (MΦ); CD11chiMHCIIhiGr-
1-F4/80- dendritic cells (DC) are shown. In normal colon tissue, only MΦ and DC populations are readily detectable
since only few MO- and PMN-IMC are normally present in the lamina propria. Representative plots of n=3 or more
experiments with 3-4 mice/experiment.
B, Representative forward scatter (FSC) and side scatter (SSC) of the predominant myeloid populations, i.e.: PMN-
IMC (CD11bhiGr-1hi), MO-IMC (CD11bhiGr-1lo) and MΦ (CD11bhiGr-1-F4/80+). Representative plot of n=3 or
more experiments with 3-4 mice/experiment.
C, Wright-Giemsa staining of cytospin-fixed MO-IMC (left) and PMN-IMC (right), FACS-sorted as Ly6ChiLy6G-
MO-IMC and Ly6CloLy6G+ PMN-IMC, respectively. Representative images of n=2 independent samples from one
cell sorting experiment with tumor samples from 2-3 mice.
D, Proportions of myeloid cell subsets in ETBF-triggered distal colon tumors versus ETBF-independent small intestine
(SI) tumors as defined by the gating strategy outlined in A. Bars represent mean ± SEM of n=3-5 independent
experiments with 3-4 mice/experiment for colon and SI tumors, respectively.
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occurring colon tumors in sham Min mice and the abundant colon tumors in ETBF
Min mice were highly infiltrated by PMN-IMC (Gr-1hi; 84% versus 70% of CD11b+
cells in sham and ETBF tumors, respectively), which in grossly normal colon tissues
constituted only a minor population (3% and 15% of CD11b+ cells in sham and
ETBF-colonized Min mice, respectively) (Figure 2.3A,B). Combined with the time-
dependent attrition of myeloid cells from the distal colon of WT mice colonized with
ETBF (Figure 2.1C), this result suggests a likely ETBF-independent but Apc LOH
dependent signal affecting myeloid cell differentiation in the TME of Min mice.
Sporadic, but not ETBF-induced tumors, were highly infiltrated by inflammatory
MΦ (Inf-MΦ) expressing high levels of F4/80 and MHC-II (23% vs. 6% of CD11b+Gr-
1lo cells, respectively). MO-IMC, on the other hand, accumulated markedly in ETBF
but to a lesser extent in sporadic colon tumors (83% vs. 57% of CD11b+Gr-1loMHC-
II-F4/80- cells, respectively, Figure 2.3A). Furthermore, Inf-MΦ isolated from spo-
radic colon tumors overexpressed Arg1 and Fizz1 (though not Ym1), hallmarks of
protumoral M2 MΦ (Figure 2.3C),154 whereas ETBF tumor-derived MO-IMC strongly
upregulated Nos2 (encoding iNOS) but not Arg1 mRNA (x10 and less than x2, re-
spectively) compared to MO-IMC isolated from sporadic colon tumors (Figure 2.3D).
Gene expression profiling revealed that sparse Inf-MΦ (6%; Figure 2.3A)) in ETBF-
Min tumors expressed H2-ab1 (encoding MHC-II), Csf1r (encoding M-CSF), Il12b
and Emr1 (encoding F4/80) (Figure 6.2), indicating a terminally differentiated state
but with lower expression of M2 markers compared to those in sporadic colon tumors
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Figure 2.3: ETBF colonization promotes specific accumulation of MO-IMC to the colon
TME
A, B, Flow cytometry analysis of myeloid cells in sporadic (sham) or ETBF-induced colon tumors (A) compared to
normal colon tissue (B) in Min mice. Histograms represent Gr-1 expression on viable CD11b+ cells (% CD11b+
indicated). Dot plots represent F4/80 and MHC-II staining in CD11b+Gr-1low (left) and CD11b+Gr-1hi cells (right).
Gr-1low encompasses inflammatory MΦ (MHC-IIhiF4/80hi) and MO-IMC (MHC-IIlow-intF4/80int) cell types whereas
Gr-1hi consists predominantly of PMN-IMC (MHC-IIlowF4/80low). Representative plots of n=5 independent experi-
ments with 2-4 mice/group. Additional representative flow cytometry plots are shown in Fig S8.
C, Arg1, Fizz1 and Ym1 expression in Inf-MΦ versus MO-IMC FACS-sorted from sporadic or ETBF tumors. Bars
represent fold increase of gene expression in inflammatory MΦ com-pared to MO-IMC, RQ (2-∆∆Ct(MΦ/MO-IMC)).
Aggregate data of n=2 independent samples from one cell sorting experiment with tumor samples from 2-3 mice/group.
D, Arg1 and Nos2 expression in MO-IMC FACS-sorted from ETBF-induced colon tumor versus MO-IMC from spo-
radic (sham) colon tumors. Bars represent fold increase of gene expression in ETBF compared to sham colon tumors,
RQ (2-∆∆Ct(ETBF/Sham)). Aggregate data of independent samples from one cell sorting experiment with tumor
samples from 2-3 mice/group. E, IHC expression of Arg1 (left) and iNOS (right) in ETBF-induced colon tumors.
Scale bar: 50 m. Representative images of n=3 or more independent experiments with 3-4 mice/experiment.
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(Figure 2.3C). Moreover, ETBF-associated MO-IMC upregulated genes such as Ido1,
Mmp9, S100a8/9, bearing resemblance to the transcriptional activity of MDSC (Fig-
ure 6.2). Lastly, IHC demonstrated that ARG1 and iNOS proteins did not co-localize
in colon tumors of ETBF-colonized Min mice (Figure 2.3E) and therefore may delin-
eate different myeloid effectors (M2-like MΦ versus MO-IMC). Taken together, these
findings demonstrate that the specific accumulation of iNOS-expressing MO-IMC is
a unique feature of the inflammatory microenvironment of colon tumors induced by
ETBF. In SI tumors (ETBF-independent) (Figure 2.2D) as well as sporadic colon
tumors (no ETBF colonization) (Figure 2.3A), levels of MO-IMC are comparatively
low.
2.2 Intratumoral but not peripheral MO-
IMC are immunosuppressive in ETBF
Min mice
We sought to determine if the distinct population of ETBF colon tumor-associated
iNOShi MO-IMC displayed an immunosuppressive phenotype in accordance with their
gene expression profile (Figure 2.3D). Although both MO- and PMN-IMC were de-
tected in the spleen, blood and colon tumors of ETBF tumor-bearing Min mice
(Figure 2.4A), only colon tumor-associated MO-IMC were immunosuppressive when
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assayed in vitro for inhibition of OVASIINFEKL-specific CD8+ T cell (OT-1) pro-
liferation (40.9 ± 4.5% of inhibition, mean ± SEM, n=3 mice/group; Figure 2.4B).
Comparatively, PMN-IMC exhibited only very modest immunosuppressive activity
on OT-1 cell proliferation (12.8 ± 3.9%, as above). Thus, the distinct MO-IMC pop-
ulation associated with ETBF colon tumors resemble MO-MDSC and will henceforth
be named as such.
We next chose to compare the transcriptomes of splenic MO-IMC and intratu-
moral MO-MDSC (3 month post ETBF colonization) to probe the mechanism be-
hind the CD8+ T cell suppression we observed. The expression of genes of interest
was quantified using Taqman qPCR. As shown in Figure 2.4C, when compared to
splenic MO-IMC from ETBF-colonized mice, intratumoral ETBF MO-MDSC exhib-
ited a higher expression of Arg1 (x129,960) and Nos2 (x110), known to be central
to arginine metabolism and Ido1 (x442), which mediates the degradation of tryp-
tophan. These metabolic pathways are all well established as key players involved
in the suppression of T cell responses.155–157 Il10 (x258), Cd274 (PD-L1, x50) and
Tgfb1 (x3) – known to contribute to inhibiting anti-tumor immunity in the TME133
– were also highly expressed in ETBF tumor MO-MDSC. Il23a, a promoter of Stat3
activation and Th17 differentiation, was strongly upregulated (x2,867). Finally, intra-
tumoral ETBF MO-MDSC overexpressed Stat3 (x3), Vegfa (x9) or Mmp9 (x5), genes
involved in tumor growth and angiogenesis. Intratumoral PMN-IMC also displayed
an immunosuppressive transcriptome (Figure 6.3). However, despite stark differences
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Figure 2.4: Colon tumor-infiltrating myeloid cells are myeloid-derived suppressor cells
A, Flow cytometry analysis of tumor, spleen and blood-derived myeloid cells in ETBF-colonized Min mice. Percent
CD45 are indicated. Representative plots of n=3 or more experiments.
B, MO-MDSC and PMN-IMC (in tumors) and IMC (in spleen) were cell-sorted from ETBF Min mice. Inhibition of
proliferation of CFSE-labeled OVA-specific transgenic CD8+ T cells (OT-1) by MDSC (T cell:IMC ratio 10:1) was
measured by dilution of CFSE using flow cytometry. Independent samples from one cell sorting experiment with n=3
mice.
C, Gene expression array in MO-MDSC (in tumors) or MO-IMC (in spleen) of 3 month ETBF Min mice. Select genes
are grouped according to biological function. Lines represent geometric mean of fold increase of gene expression (RQ)
in tumor MDSC versus spleen IMC. Dots rep-resent RQ values from individual cell sorting experiments. Aggregate
data of n=3 independent experiments with pooled tumor samples of 3-4 mice/experiment.
D, In vitro derived MO-IMC were adoptively transferred into Min mice with established colon tumors (2 months post
ETBF colonization). 7 days after transfer, MO-IMC were harvested from spleen or colon tumors and Nos2 and Arg1
gene expression was analyzed. Ct values were normalized with CtGapdh (∆Ct=Ct-CtGapdh) and bars represent
2-∆Ct. Aggregate data of n=2 independent experiments with 2-3 mice/experiment. nd=not detected.
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in their in vitro inhibitory capacities (Figure 2.4B), a direct comparison of TME-
resident MO-MDSC and PMN-IMC showed no major differences in transcriptional
programs (Figure 6.4), with the exception of the genes CCR2 (chemokine receptor
mediating myeloid trafficking) and Il6 (protumoral cytokine via Stat3 activation),
which were both upregulated only in MO-MDSC. Collectively, these results support
the conclusion that ETBF induces a distinct population of immunosuppressive, pro-
tumoral MO-MDSC in the colon TME, which are predicted to play a key role in
ETBF-induced inflammatory carcinogenesis.
As our research group recently reported, we found that Il17a was expressed in
intratumoral ETBF MO-MDSC but not splenic MO-IMC (Figure 2.4C).65 We ruled
out contamination by Il17a derived from T cells (including CD4+, CD8+, γδ+, NKT
cells) by flow cytometry (Figure 6.5) and Cd3e qPCR (data not shown). However,
although Il17a gene expression appeared to selectively delineate intratumoral MDSC
(especially MO-MDSC) (Figure 6.6A), IL-17 protein was not detected by intracellu-
lar cytokine staining.65 Nonetheless, Il17a expression by MO-MDSC correlates with
their selective activation in the TME: when comparing gene expression 7 days after
ETBF colonization in MO-MDSC and MO-IMC harvested from Min or WT mice
respectively, we found IL-17 to be differentially regulated between groups, and highly
expressed only in Min (x146, Figure 6.6B). T cells isolated from Min versus WT
mice displayed only modestly greater IL-17 expression (x5). Additional transcrip-
tion factors that typically regulate Il17a transcription, such as Rorc, Il23r and Irf4,
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were expressed in colon lamina propria-infiltrating MO-MDSC 7 days after ETBF
colonization at levels comparable to those found in infiltrating T cells (Figure 6.6B),
with the exception of Rorc, which was markedly increased only in MO-MDSC iso-
lated from Min distal colon (x596). IL17a and Rorc expression, together with that
of Nos2, may constitute activation markers specifically identifying ETBF-associated
tumor MO-MDSC.
To further confirm the ability of the ETBF-associated TME to polarize IMC
towards MO-MDSC, we adoptively transferred WT CD45.1+ BM-derived MO-IMC
into 2-month ETBF-colonized or sham-inoculated CD45.2+ Min mice. We compared
the gene expression profile of CD45.1+ BM-derived MO-IMC prior to and 7 days after
transfer, when they were cell-sorted from spleen and colon tumors of the recipient
mice. Nos2 was strongly upregulated in adoptively transferred cells isolated from
colon tumors, but not spleen, of the ETBF Min recipients. Arg1 expression declined
compared to pre-transfer BM-derived MO-IMC (Figure 2.4D), consistent with data
in Figure 2.3D.
In summary, our findings demonstrate that the ETBF-associated colon TME
in Min mice uniquely promotes the differentiation to and recruitment of iNOShi
MO-MDSC (also marked by Il17a and Rorc expression), which are characterized
by the capacity to suppress T cell responses as well as to provide tumor growth,
pro-angiogenesis and pro-inflammatory factors.
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2.3 Endogenous IL-17 mobilizes and acti-
vates MDSC during de novo ETBF-
induced colon tumorigenesis
Next, we sought to identify tumor-associated signals accounting for MO-MDSC
recruitment and their activation in ETBF-induced colon tumors. Since we previ-
ously demonstrated that IL-17 is critical to ETBF-triggered colon carcinogenesis,
and the accumulation of protumoral MDSC in the TME was recently attributed to
IL-17,19,152,153,158 we postulated that intratumoral IL-17 was, at least in part, re-
sponsible for the selective accumulation and activation of pro-carcinogenic iNOShi
MO-MDSC in the colon tumors of ETBF-colonized Min mice. To test this hypoth-
esis, we demonstrated that IL-17R-expressing MO-MDSC (Figure 2.4C) sorted from
colon tumors of ETBF Min mice could be activated in response to recombinant IL-
17 (rIL-17). Crucially, the ETBF TME is IL-17-rich and purified MO-MDSC are
likely pre-conditioned, therefore the response to exogenous IL-17 may be suppressed.
Notwithstanding, ex vivo treatment of purified MO-MDSC with rIL-17 induced sig-
nificant upregulation of Nos2 and modest upregulation of Arg1, genes involved in T
cell immunosuppression (Figure 2.5A). In addition, we observed a trend to upregulate
Stat3, which is strongly associated with protumoral activity, as well as proinflamma-
tory genes such as Cybb (encoding NOX2), Ptgs2 (encoding COX2) or Stat1, in
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response to rIL-17 treatment. As shown in Figure 2.4C and Figure 6.2, many of these
genes were also overexpressed in vivo in ETBF tumor-derived MO-MDSC. In contrast,
splenic MO-IMC isolated from ETBF-colonized Min mice were unable to upregulate
Arg1 or Nos2 in response to rIL-17, despite comparable IL-17ra mRNA expression
(data not shown), suggesting the notion that additional ETBF-driven mucosal (i.e.
CEC or TME-derived) signals act in conjunction with IL-17 to promote protumoral
and immunosuppressive MDSC. Consistent with this idea, the upregulation of IL-10
and IL-23 gene transcription in vivo together with that of Stat3 underscored the likely
contribution of paracrine feedback signaling on the expression of STAT3 (i.e. STAT3
activation is downstream of the IL-10 and IL-23 receptors), and suggests that STAT3
may serve as an important signal transducer of IL-17-mediated MDSC activation.63,74
Further, we found that the enhanced transcriptional activity of Nos2 correlated
with increased nitric oxide protein expression. rIL-17 increased in vitro iNOS activity
as measured by the production of nitric oxide (NO) in the culture supernatant of
LPS-conditioned MO-MDSC (Figure 6.7). Spleen-derived MO-IMC were unable to
produce NO upon in vitro stimulation.
Finally, using ETBF-colonized mixed BM chimeric Min mice — generated by re-
constituting lethally irradiated Min mice with a 1:1 mixture of CD45.1+IL-17R+/+
and CD45.2+IL-17R-/- BM – we showed that CD45.1+IL-17R+ MO-MDSC (i.e. sensi-
tive to endogenous IL-17) sorted from colon tumors 10 weeks after ETBF inoculation
exhibited a higher expression of Nos2, Arg1, Il23a, Ptgs2 (Cox2), Cd274 (PD-L1)
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Figure 2.5: IL-17-induced protumoral transcriptomes in tumor-infiltrating MO-MDSC
A, Tumor MO-MDSC sorted from ETBF Min colon tumors were incubated overnight with rIL-17 (10 ng/ml) and
gene expression was assessed by qPCR. Lines represent geometric mean of 2-∆Ct in MO-MDSC cultured with IL-17
compared to medium alone. Dots represent 2-∆Ct values from individual cell sorting experiments. Fold increase of
gene expression are indicated below gene labels. Increase of Nos2 expression in IL-17-treated cells was significant with
p=0.0055 (ratio paired t test). Aggregate data of n=3-4 independent experiments with 2-3 mice/experiment.
B, Ex vivo gene expression in CD45.2+IL-17R- MO-MDSC (white bars) and CD45.1+IL-17R+ MO-MDSC (black
bars) sorted from colon tumors of 2 month ETBF-colonized [CD45.2+IL-17R-/CD45.1+IL-17R+] mixed bone marrow
(BM) chimera Min mice. Bars represent 2-∆Ct. Fold increase of gene expression between CD45.1+IL-17R+ vs.
CD45.2+IL-17R- MDSC are indicated above the black bars. Representative data of independent samples from one
cell sorting experiment with n=2 mice.
C, Flow cytometry of myeloid populations infiltrating colon tumors of one month ETBF-colonized mixed BM chimera
[CD45.2+IL-17R-/CD45.1+IL-17R+] Min mice. Percentages and phenotype of CD45.2+ (IL-17R-/-) versus CD45.1+
(IL-17R+/+) myeloid populations were compared. CD11b and Gr-1 expression were analyzed in CD45.1+ and
CD45.2+ cells independently. Representative plots of n=2 independent experiments with 3-4 mice/experiment.
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and Tnfa (all IL-17 dependent genes) as compared to CD45.2+IL-17R-/- MO-MDSC
(Figure 2.5B). These results, together with our previous identification of many of
the same transcripts in MO-MDSC cultured in vitro with exogenous rIL-17 (Figure
2.5A), demonstrate direct involvement of IL-17 in establishing protumoral MO-MDSC
in the ETBF-induced TME. S100A9, a Stat3-dependent gene responsible for MDSC
accumulation and activation , was not differentially regulated by IL-17, which signals
predominantly through NF-B, emphasizing that several regulatory pathways act in
tandem to fully activate MDSC.
Interestingly, although reduced in numbers compared to CD45.1+IL-17R+CD11b+
cells, CD45.2+IL-17R-CD11b+ cells were still present in the colon TME (69% CD45.1+
cells versus 26% CD45.2+ cells, respectively; Figure 2.5C), again implying that sig-
nals in addition to the direct action of IL-17 on IMC coordinated MDSC recruitment
to the ETBF colon TME. Nevertheless, the proportions of MO-MDSC and other
myeloid cells subsets (CD45.2+CD11bhiGr-1-), including MΦ and DC, were drasti-
cally decreased in IL-17R-deficient tumor-infiltrating CD45.2+ cells compared to cells
derived from CD45.1+IL-17R+ hematopoietic progenitors. Notably, the proportion of
PMN-MDSC in tumors decreased two fold in the IL-17R-deficient tumor-infiltrating
CD45.2+ cells compared to CD45.1+IL-17R+ cells (2.3% to 4.7%, respectively), indi-
cating a similar dependency on IL-17 (Figure 2.5C). These results highlight the ability
of IL-17 to preferentially activate MO-MDSC in vivo and drive their accumulation
to the TME. However, other stimuli act in concert with IL-17 to mold the overall
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myeloid TME in ETBF-colonized Min mice.
2.4 Recruitment of IL-17-driven, iNOS-
expressing MO-MDSC constitutes an
immune signature of ETBF colon tu-
morigenesis
Our final aim was to address whether the myeloid environment that is estab-
lished upon colonization with ETBF and is associated with ETBF-triggered colon
tumorigenesis is specific to ETBF or common among oncogenic bacteria. To test
for specificity, we compared ETBF colonization of WT mice with Fusobacterium nu-
cleatum and pks+ E. coli, two bacteria strongly associated with CRC in humans10
and shown to induce colon tumorigenesis in experimental murine models.20,22 As a
control, we used the non-colitogenic Bacteroides fragilis 9349 pfd340 (NTBF) and E.
coli lacking the genotoxic pks island (E. coli ∆pks).
Although mice were successfully colonized with each bacterium (Figure 6.8), only
ETBF and Fusobacterium induced a strong myeloid response upon colonization, which
was characterized by an increased proportion of MO- and PMN-IMC in the distal
colon by day 7 post-colonization (Figure 2.6A). This aligns with studies by Kostic et
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Figure 2.6: Mucosal immune response to Fusobacterium nucleatum, pks+ E. coli, ETBF
and NTBF colonization in WT mice
A, Proportion of CD11b+Ly6ChiLy6G- MO-IMC (white bars) and CD11b+Ly6ClowLy6G+ PMN-IMC (black bars)
as percent of viable CD45+ leukocytes isolated from distal colon of WT mice one week post-infection with oncogenic
bacteria listed along the x-axis.
B, Absolute numbers of Th1 (CD3+CD4+IFN-γ+, Th17 (CD3+CD4+IL-17+), cytotoxic T cells (CD3+CD8+IFN-
γ+) and γδ T cells (CD3+γδ+IL-17+) lymphoid populations isolated from distal colon as described in A.
Aggregate data of n=2 independent experiments with 3 mice per group.
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al.22 who showed an increase of myeloid subsets in small intestinal tumors following
daily inoculation of Min mice with Fusobacterium for 8 weeks; colon tissues were not
examined. It is worth pointing out that the authors used SI tumors as a surrogate
for the TME in colon tumors. Per contra, in the context of ETBF infection, SI and
colon tumors attract distinct myeloid populations (as shown in Figure 2.2D).
Infection with pks+ E. coli had little impact on myeloid recruitment, consistent
with published findings comparing oncogenic E. coli to control E. faecalis in which
neither lymphoid (CD3) nor myeloid (as measured by Ly6B, F480 immunohisto-
chemistry) responses differed.20 However, and in stark contrast to ETBF,19 no other
oncogenic bacterium triggered a predominant production of IL-17 (Figure 2.6B). Al-
together, these results demonstrate that high IL-17 levels in combination with MO-
MDSC accumulation may mark the pathogenic interaction of ETBF with colon CEC
and be considered as the immune signature of tumorigenic ETBF infection.
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Figure 2.7: Proposed model for IL-17 recruitment of MDSC into colon TME of ETBF-
colonized Min mice
ETBF induces submucosal IL-17 expression, which orchestrates the myeloid environment of ETBF-triggered colon
tumors both directly by interacting with myeloid IL-17 receptors and indirectly by further inducing the ectopic
production of chemokines and/or growth factors by dysplastic IL-17R+ colonic epithelial cells (CEC). The combined
action of IL-17 and transformed CECs drives MDSC to promote tumor growth via the suppression of immune effector





We show herein that ETBF-triggered de novo colon carcinogenesis in Min mice
leads to the specific recruitment and activation of MO-MDSC. We conclude that
ETBF affects the myeloid compartment in two ways. First, ETBF-induced intratu-
moral IL-17 together with additional factors, likely epithelial-derived, orchestrate the
recruitment of myeloid cells to the TME. Second, BFT-driven oncogenesis polarizes
the differentiation of IMC towards MDSC. We identified an ‘immune signature’ as-
sociated with ETBF-driven colon tumorigenesis, defined by high levels of IL-17 and
an accumulation of iNOShigh MO-MDSC. This was radically different from the TME
observed in ETBF-independent SI tumors, which were more infiltrated by MC and
less by MDSC, or sporadic colon tumors, which presented with a higher proportion
of M2 MΦ and few MO-MDSC (Figures 2.2 and 2.3). Finally, among bacteria linked
to the etiology of CRC, the immune landscape associated with ETBF infection was
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unique, affirming the distinct mechanisms via which these pathobionts can initiate
and promote tumorigenesis.
Importantly, since ETBF accelerates the tumorigenesis process observed in the
colons of Min mice, we cannot formally rule out that the differences in the propor-
tions of MΦ and MO-MDSC between sham and ETBF-triggered tumors was not a
consequence of rapid recruitment of IMC to the ETBF-associated TME rather than of
skewed myeloid differentiation related to the inflammatory and metabolic conditions
within the ETBF-associated TME. However, the adoptive transfer of BM-derived
IMC demonstrated that they were:
1. recruited to the ETBF-associated TME and
2. upregulated Nos2 (Figure 2.4D) and Il17 gene expression (Figure 6.6).
Recruitment, together with Nos2 and Il17 expression were hallmarks of MO-MDSC
activation in this study. This result supports a specific role of ETBF on altered
myeloid differentiation in the TME rather than a kinetic effect. Namely, peripher-
ally injected BM-derived IMC (iNOSlow) differentiated into intratumoral MO-MDSC
(iNOShi) within one week in ETBF-colonized Min mice.
In this study, IL-17 acted as a key inflammatory mediator for myeloid recruitment
and polarization. Genetic ablation of IL-17R in the hematopoietic compartment pro-
foundly affected proportions of MO-MDSC in the TME of ETBF Min mice, but did
not abrogate myeloid recruitment. Recent studies in human CRC as well as numerous
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mouse models have proposed that IL-17 is critical for recruitment of MDSC to the
TME.73,152,158,159 However, sporadic colon tumors (that result from Apc deletion but
not ETBF activity) are also infiltrated by Th17 cells (unpublished results), though
without the accumulation of MO-MDSC, proof that additional ETBF-dependent ep-
ithelial signals, yet to be identified, shape local myelopoiesis.
The primary virulence determinant of ETBF is bft.160 Bft is a metalloprotease
that upon binding to a putative colonic epithelial cell receptor triggers cleavage of
E-cadherin, thereby releasing E-cadherin-associated β-catenin and consequently ac-
tivating Wnt (targeting c-Myc and resulting in epithelial proliferation)61 and, sep-
arately, NF-κB (targeting proinflammatory mediators)51 signaling pathways. BFT-
induced production of IL-8 by human colonic epithelial cells, a NF-κB-dependent fac-
tor, and its murine homologue, CXCL1, can direct MDSC recruitment.158,161 Herein,
we demonstrated that ETBF has the capacity to shape the inflammatory environ-
ment differently in CECApc/- versus WT epithelia (no Apc deletion but intact BFT
activity), resulting in a specific immune signature observable in Min colon tissue. In
contrast, no sustained accumulation of MO-MDSC was evident in WT mice.
Select bacteria and their virulence factors can shape the colonic mucosal immune
response, resulting in immune signatures defined by distinct proinflammatory gene
expression profiles and the presence of specific immune cell subsets. Fusobacterium
nucleatum which is enriched in a subset of colorectal carcinoma tissue samples was
suggested to accelerate colon tumorigenesis in Min mice via the polarization of the
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myeloid compartment in absence of histologic colitis and Th17 activation.22 Similarly,
pks+ E. coli strains were shown to promote colon tumorigenesis in the context of
experimentally-induced colitis via colibactin, encoded in the pks island with the ability
to trigger DNA-damage.20 Our findings herein, together with recently published
data, collectively propose that the TME associated with ETBF colon tumors likely
results from the combined action of BFT, IL-17 and a permissive genetic background
(CECApc-/-).19,65,71,162 It will be critical to investigate IL-17R-expressing tumor CEC
under the influence of IL-17 and BFT, and identify mediators capable of polarizing
the myeloid compartment towards protumoral MDSC (Figure 2.7).
How and whether MDSC, in particular MO-MDSC, contribute to ETBF-driven
colon tumorigenesis remains unknown. We report here that colon tumor-infiltrating
iNOShigh MO-MDSC suppressed antigen-specific CD8+ T cell responses in vitro, sug-
gesting that the selective accumulation of immunosuppressive MO-MDSC in ETBF-
colonized Min mice may account, at least in part, for the development of gross colon
tumors. While in vitro inhibition of T cell proliferation is considered a poor sur-
rogate of in vivo immunosuppression, the concomitant gene expression profiling of
MO-MDSC, displaying a strong upregulation of inhibitory metabolic enzymes (Arg1,
Nos2 and Ido), immune checkpoint ligands (PD-L1) and soluble mediators (Il10 and
Tgfb1) among other genes supports our conclusion that tumor-infiltrating MO-
MDSC are potent suppressors of anti-tumor immunity. Furthermore, in the context
of intestinal chronic inflammation, by inhibiting Th1 responses and producing high
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levels of IL-1, IL-6 (not shown) and IL-23 (Figure 2.4C), MDSC in the ETBF TME
may contribute to the recruitment of Th17 and amplify IL-17-driven ETBF oncoge-
nesis, while, simultaneously, contributing to the promotion of tumors by enabling an
environment permissive for tumor growth and angiogenesis.158 This agrees with recent
findings that IMC are capable of promoting carcinogenesis via mechanisms other than
T cell inhibition.163 Furthermore, it supports our observation that ETBF-associated
MO-MDSC were immunosuppressive in vitro even though they did so at fairly modest
levels (approximately 40% inhibition of proliferation) compared to suppression levels
of 80-90% typically reported for MDSC.164
Human and murine observations suggest that long term carriage of ETBF with
subclinical colon inflammation may have oncogenic consequences and support the
notion that ETBF is a novel candidate for initiation/promotion of human colon car-
cinogenesis. We show herein that a specific IL-17+ MO-MDSC-dominant immune
signature is associated with ETBF tumorigenesis. In humans, we postulate that
identification of similar immune signatures in ETBF-infected individuals may be pre-
dictive of malignant transformation. Longitudinal studies are required to assess if
the use of cellular and molecular immune signatures as a biomarker holds promise of
identifying individuals at risk for developing cancer, and for whom early eradication




4.1 Targeting critical signaling pathways
in MDSC
The ability of MDSC to suppress anti-tumor immune responses and supply pro-
tumoral factors is dependent on a two-step process:
1. Recruitment and
2. activation.
Stat3 and NF-κB are examples of signaling pathways which are critical to both
processes and play overlapping roles.154 Our findings showed that ETBF-driven tu-
morigenesis in Min mice is characterized by the accumulation of IMC to the tumor
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microenvironment and their subsequent activation to MO-MDSC. Thus, we hypoth-
esized that disruption of critical signaling pathways in MDSC may inhibit their func-
tion, and reduce their purported oncogenic activity. In the ETBF Min model, tumor
numbers in the murine distal colon correlated with the severity of pro-tumoral inflam-
mation.19 Therefore, we generated BM chimera Min mice with conditional deficiency
of either Stat3 or MyD88 myeloid compartment, and challenged the mice with ETBF
to trigger colon tumors. MyD88 is a universal adapter protein used by toll-like recep-
tors to activate NF-κB. Unexpectedly, Stat3 or MyD88 knockout BM chimera mice
were not protected from tumorigenesis: tumors developed in numbers comparable to
WT mice (see Figure 4.1A, B).
Similar experiments were conducted in BM chimera Min mice lacking CSFR3 (en-
coding the G-CSF receptor). Chung et al. showed that an IL-17-mediated paracrine
network induced G-CSF through NF-κB and ERK signaling, leading to IMC mobi-
lization and recruitment to the murine colon tumor micronenvironment.73 CSFR3-/-
mice had fewer circulating and tumor-associated MDSC and exhibited delayed growth
of transplanted EL-4 tumors following α-VEGF antibody treatment. Welte et al. re-
ported that mTOR signaling in cancer cells stimulates MDSC accumulation through
the regulation of G-CSF.165 However, we observed no differences in tumor counts




Hif-1α is another critical regulator of MDSC function: it controls suppressive ac-
tivity and drives their differentiation to tumor-associated macrophages.98 We crossed
conditional Hif-1α knockout mice to Min mice and subsequently infected them with
ETBF. At 12 weeks of colonization, tumor counts revealed no significant differences
between knockout and WT groups (see Figure 4.1C). Notably, LysMcre mediated dele-
tion of Hif-1α in the myeloid compartment was more than 80% efficient, suggesting
that our observations were not due to insufficient penetrance of the knockout genotype
(data not shown).
We performed additional experiments aimed at reducing tumorigenesis in the
ETBF Min model, employing established pharmacological tools such as α-Gr-1 anti-
body treatment or phosphodiesterase-5 (PDE-5) inhibitors to target MDSC. In pre-
vious studies, α-Gr-1-mediated depletion of MDSC enhanced the activity of antigen-
presenting cells and increased the frequency and activity of NK and T cell effectors
in a murine lung cancer model.166 Sildenafil, a PDE-5 inhibitor, has been reported to
down-regulate Arg1 and Nos2 expression, thereby reducing the suppressive machinery
of MDSC.167 In our hands, neither treatment was successful in reducing ETBF Min
tumorigenesis (data not shown).
In sum, our experiments showed that single pathway inhibition in MDSC was not
sufficient to impact ETBF tumorigenesis. Likely, a combination of robust myelopoiesis
and redundant pathways may have counteracted all genetic or pharmacological tar-
geting strategies. With only partial therapeutic efficacy, MDSC were recruited to
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the tumor microenvironment and subsequently activated in large enough numbers to
allow progression.
4.2 The CXCR2 inflammatory chemokine
receptor
Numerous treatment options are being explored for the pharmacological regula-
tion of MDSC (summarized in154). A novel approach involves the inhibition of the
CXCR2 inflammatory chemokine receptor, a heptahelical G protein-coupled receptor
that mediates the biological effect of inflammatory chemokines. The differential ex-
pression of inflammatory chemokine receptors can be utilized to delineate MO- and
PMN-MDSC (see Figure 6.11). CXCR2 is a key regulator of recruitment and effector
responses of Ly6G-expressing neutrophils. Mei et al. proposed a model in which
neutrophil-expressed CXCR2 is required for migration into tissues, especially mu-
cosal sites, to downregulate the IL-17/G-CSF axis. Colon epithelial cell express the
CXCR2-ligand and chemoattract CXCL5 to promote neutrophil transmigration to
the gut, where they regulate granulopoiesis and neutrophil homeostasis through feed-
back inhibition of IL-17/G-CSF.168 Importantly, CXCR2 is also expressed by MDSC
in tumor-bearing mice.114,169
Research by the group of Raymond DuBois showed that COX-2 and the COX-2
derived prostaglandin E2 (PGE2), which is potently induced by pathogenic bacte-
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Figure 4.1: Disruption of critical MDSC signaling pathways does not impact
tumorigenesis in ETBF Min mice
A, BM from WT or LysMcre Stat3fl/fl donors was transferred to Min recipients to generate
BM chimera Min. 6 weeks after transfer, mice were infected with ETBF. 12 weeks later,
the colon was harvested for tumor scoring.
B, As above, except with LysMcre MyD88fl/fl donor mice.




ria from the gut flora, can stimulate CRC cells to produce another CXCR2 ligand,
CXCL1.170 Using the AOM/DSS model of colitis-associated cancer, they show that
loss of CXCR2 suppresses chronic colonic inflammation and tumorigenesis in a MDSC-
dependent manner.171
In light of this data we hypothesized that high levels of IL-17, a hallmark of
ETBF inflammation, may trigger recruitment of PMN-MDSC to the Min colon via
the CXCL chemokine/CXCR2 axis. We confirmed that CXCR2 is expressed in
ETBF tumor-associated PMN-MDSC (see Figure 6.10A). We found that the CXCR2-
ligands CXCL1, CXCL2 and CXCL5 are all upregulated in distal colon epithe-
lium segments of ETBF versus sham-inoculated mice (Figure 4.2A). Importantly,
ETBF-induced CXCL chemokine upregulation was dependent on IL-17 signaling,




Figure 4.2: ETBF induces expression of the CXCR2 ligands CXCL1, CXCL2
and CXCL6 in distal colon epithelium segments in an IL-17-dependent manner
A, Expression of Il17a, Cxcl1, Cxcl2 and Cxcl5 relative to Gapdh in 1 week ETBF-infected
WT or sham-inoculated mice. Expression was quantified in individual colon segments (C1
through C6, representing segments from the distal to proximal colon, respectively).
B, As above, except in ETBF-inoculated WT versus IL-17-R-/- (left) and IL-17-/- (right)
mice.
Courtesy of Abby Geis and Liam Chung.
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4.3 Inhibition of CXCR2 suppresses re-
cruitment of MDSC to the ETBF-inflamed
colon and reduces tumorigenesis in Min
mice
Next, we sought to characterize ETBF-inflammation in CXCR2-/- mice. As previ-
ously reported, knockout of CXCR2 results in potent suppression of neutrophil trans-
migration to inflammatory sites, i.e. the inflammatory tumor microenvironment, as
evident by the reduction of Ly6G+ MPO+ neutrophils in DMBA/TPA-induced skin
papillomas172 and PMN-MDSC in AOM/DSS-induced colon tumors.171 We confirmed
by flow cytometry that expression of CXCR2 was absent at the surface of distal colon-
infiltrating PMN cells from ETBF-infected CXCR2-/- mice (see Figure 6.10B).
As shown in Figure 4.3A, PMN-IMC were significantly reduced in CXCR2-/- mice
during acute infection with ETBF (7 days). MO-IMC and macrophages were not
affected. In particular, the inflammatory IL-17 response — mediated chiefly by Th17
and γδ T cells65 — was not negatively impacted, contrariwise IL-17+ trended to be
increased in CXCR2-/-. This is consistent with reports of Mei et al.,168 where IL-1β
and IL-23-responsive IL-17producing cells were significantly increased in tissues of
CXCR2-deficient mice relative to WT.
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To extend these findings to the Min mouse model, we chose to use a synthetic
peptide inhibitor of CXCR2, pepducin. Pepducins were developed by Kaneider et
al. to specifically target the CXCR chemokine receptors, and originally devised to
block sepsis in mice.173 They were also used by Jamieson et al. to illustrate the
requirement of CXCR2 for spontaneous tumorigenesis: daily pepducin treatment of
Min mice suppressed the spontaneous development of benign intestinal adenomas.172
In agreement with our findings in ETBF-infected CXCR2-/- mice, pepducin-treated,
ETBF-infected Min mice exhibited significantly reduced PMN-IMC numbers (Fig-
ure 4.3B). M1 macrophages, characterized by high surface expression of MHC-II and
F4/80, were increased in pepducin-treated mice, although not statistically significant.
As in CXCR2-/- mice, IL-17-secreting lymphocytes trended to be increased.
In an attempt to establish whether inhibition of CXCR2 can reduce tumorige-
nesis in the ETBF Min model, we generated bone marrow chimeras with Min re-
cipients and CXCR2-sufficient or deficient donors. As expected, their characteriza-
tion revealed that PMN-MDSC were drastically reduced in ETBF-induced colon tu-
mors of CXCR2-/- Min chimera mice (Figure 4.3C). Reaffirming the specificity of the
CXCLX :CXCR2 interaction (which occurs primarily at mucosal sites), PMN-MDSC
levels in the spleen were comparable between knockout and WT chimera mice. Strik-
ingly, M1 macrophages were again increased in knockout versus WT chimeras (Figure
4.3D). Tumor counts revealed that CXCR2-/- mice had significantly fewer colon tu-
mors after longterm ETBF colonization (12 weeks, Figure 4.3E), despite equivalent
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levels of Il17 mRNA in distal colon tissue samples (data not shown).
Thus, in contrast to the disruption of signaling pathways in MDSC, which re-
mained largely unsuccessful in abrogating tumorigenesis, inhibition of MDSC recruit-
ment to the distal colon succeeded. This is a significant observation for the following
reasons:
• Of numerous transgenic strains on a Min background, only IL-17A, IL-17R
and Stat3 knockouts have been protected from ETBF-induced tumorigenesis.
The CXCR2-/- mouse now joins these strains, demonstrating that it is a strong
modifier of pro-tumoral MDSC function.
• As we described in Chapter 2, MO-MDSC emerged as the distinct myeloid
population associated with ETBF-triggered colon tumors. In contrast, both
sporadic and ETBF-induced Min colon tumors were highly infiltrated by PMN-
MDSC (Figure 2.3), which upregulated S100A8/9 and Mmp9 as compared to
MO-MDSC (Figure 6.4). However, MO-MDSC do not express CXCR2 and are
not numerically reduced in CXCR2-/- mice. Thus, our findings that reduction of
PMN-MDSC correlates with tumor suppression must be reconciled therewith.
Notably, the mechanism via which inhibition of PMN-MDSC is anti-tumoral
is poorly understood. Perhaps recruitment of PMN is a common tumorigenic
mechanism in both inflammation-induced and sporadic tumors, while MO may
act as a specific pro-tumoral modifier (tumorigenesis is markedly accelerated by
ETBF). Further studies are necessary to explore whether inhibition of CCR2, a
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chemokine receptor expressed predominantly by MO-MDSC (see Figure 6.11),
can achieve tumor reduction.
• M1 macrophages were increased across all models of CXCR2 inhibition. Phe-
notypically, they resembled inflammatory macrophages, which also occurred
in high numbers in sporadic Min colon tumors. We may speculate that the
CXCR2-/- anti-tumor effect is achieved in part through a modified myeloid im-
mune infiltrate, characterized by mature macrophages exhibiting an M1 pheno-
type.
• We observed that CXCR2 ligands are upregulated in distal colon segments, with
increasing expression from proximal to distal (Figure 4.2). By comparison, IL-
17 levels are consistently elevated throughout the colon, mirroring the uniform
colonization of ETBF in the entire colon mucosa.64 However, tumorigenesis
occurs predominantly in distal segments. Future studies may provide insight
into whether a CXCL chemokine gradient precludes tumor localization.
• Experiments to address whether pepducin administered to longterm ETBF-
colonized Min mice may reduce tumorigenesis are ongoing.
Our data supports the notion that CXCR2 is a leading mechanism for the recruit-
ment of MDSC to tumor sites, and its inhibition may prove to be a powerful tool to
study MDSC biology. The ability to selectively target specific myeloid populations by
excluding their migration to the tumor microenvironment will enable deeper under-
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standing of their contribution to tumorigenesis. Lastly, pharmacological development
of MDSC-specific chemokine receptor inhibitors for clinical use may pave the way for




















































































































































Figure 4.3: Inhibition of CXCR2 suppresses recruitment of MDSC to the ETBF-
inflamed colon and reduces tumorigenesis in Min mice
Continued on next page.
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Figure 4.3: Inhibition of CXCR2 suppresses recruitment of MDSC to the ETBF-
inflamed colon and reduces tumorigenesis in Min mice
A, Relative abundance of myeloid and lymphoid populations in distal colon of 1 week ETBF-
colonized WT or CXCR2-deficient mice. MO-IMC, PMN-IMC, MΦ, Th17 and γδ T cells
are shown in percentage relative to CD45+ leukocytes.
B, As above, except in ETBF-inoculated Min mice that received pepducin, a CXCR2 an-
tagonist, or control peptide. M1 and M2 MΦ are characterized by high or low F4/80 and
MHC-II expression, respectively.
C, Recovery of MDSC populations in colon tumors or spleen of longterm ETBF-colonized
CXCR2+/+ or CXCR2-/- BM chimera Min mice, shown as percent CD11b+ myeloid cells.
D, Proportion of M1 MΦ in colon tumors of CXCR2+/+ or CXCR2-/- BM chimera mice as
percent CD11b+ myeloid cells.





5.1 Mice and bacteria
C57BL/6 (wildtype, WT), CD45.1 C57BL/6 and Min (Apc∆716/+) mice were pur-
chased from The Jackson Laboratories (Bar Harbor, ME) or obtained from Dr. David
Huso (Johns Hopkins University) and bred in the vivarium. OT-1 T cell receptor
transgenic RAG-/- mice were bred in-house. Mixed bone marrow (BM) chimeric mice
were established by intravenous injection of 107 BM cells from donor mice into lethally
irradiated (900 cGy) recipient mice. Unless otherwise stated, n=2-4 mice were used
per experimental group, the colon of each mouse was processed independently and,
thus, data reflects measurements in individual mice. Mice were maintained accord-
ing to protocols approved by the Johns Hopkins University Animal Care and Use
Committee. ETBF strain 86-5443-2-2, NTBF strain 9343 pfd340, Fusobacterium nu-
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cleatum strain 2432 (provided by Brandon Ellis, Johns Hopkins Medical Microbiology
Laboratory), pks+ E. coli strain NC101 and E. coli ∆pks strain NC101 (provided by
Dr. Christian Jobin, University of Florida) were used in this study. Mice were chal-
lenged at 4-6 weeks of age following per os antibiotic pre-treatment (clindamycin and
streptomycin) and harvested at the time points described.19 BM chimeric mice were
inoculated 6 weeks after BM engraftment. Fecal samples were cultured periodically
post-inoculation to quantify and assure consistent ETBF colonization.
5.2 Leukocyte isolation from gut lamina
propria, tumors and spleen
Small intestine and distal colon (Figure 6.1) were cut, washed and enzymatically
digested (400 U/ml Liberase and 0.1 mg/ml DNAse1; Roche Diagnostics, Indianapo-
lis, IN). Colon and blood leukocytes were isolated using Percoll gradient separa-
tion (GE Healthcare Life Science, Pittsburgh, PA). Splenocytes were isolated from
Liberase-treated spleen samples using Lymphoprep density gradient (Accurate Chem-
ical & Scientific Corporation, Westbury, NY).
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5.3 Flow cytometry and cell sorting
Single cell suspensions were stained with Live/Dead Yellow (Life Technologies,
Grand Island, NY), CD11b-PerCp/Cy5.5 (M1/70, Biolegend, San Diego, CA), I-
A/I-E-AF488 (M5/114.15.2, Biolegend), Gr-1-Pacific Orange (RB6-8C5, Life Tech-
nologies), F4/80-PE-Cy7 (BM8, Biolegend), CD11c-APC-Cy7 (HL3, BD Biosciences,
San Jose, CA), CD117-PE-Cy5 (2B8, Biolegend) and FcϵRI (Mar-1, Biolegend). Ly6-
C-Pacific Blue (HK1.4, Biolegend) and Ly6-G-AF647 (1A8, Biolegend) were used in
adoptive transfer experiments. For intracellular cytokine staining, cells were stimu-
lated for 4.5 h with 30 nM phorbol 12-myristate 13-acetate and 1 M ionomycin (both
eBioscience) in presence of Golgistop (BD). Cells were subsequently stained against
cell surface markers (CD4-PerCp/Cy5.5, GK1.5; CD3-AF700, 17A2; CD8-PE/CF594,
53-6.7; all Biolegend) followed by fixation/permeabilization (Cytofix/Cytoperm, BD)
and staining using IL-17A-Pacific Blue (TC11-18H10.1, Biolegend). Flow cytometry
was performed using a LSRII cytometer (BD) and data was analyzed with FACSDiVa
6.1.3 software (BD). For cell sorting (FACS) experiments, myeloid populations were
sorted using an AriaII cytometer (BD).
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5.4 Suppression of antigen-specific prolif-
eration
FACS-sorted IMC were co-incubated with CFSE-labelled OT-1 CD8+ T cells at
T cell:IMC ratios of 10:1 or 1:1 in the presence of 1 µg/ml OVASIINFEKL peptide.
Irradiated splenocytes were used as source of antigen-presenting cells. Proliferation
was measured as dilution of CFSE and assessed by flow cytometry. Inhibition of
proliferation was measured as 100 x [1-(% CFSElow OT-1 in co-culture with MDSC
/ % CFSElow OT-1 alone)].
5.5 Nitric oxide assay
FACS-sorted MO-MDSC were cultured for 16 hours in MEM medium alone or in
the presence of recombinant mouse IL-17A (Biolegend) and LPS-B5 (Invivogen, San
Diego, CA). Culture supernatants were screened for nitric oxide production using a
NO detection kit (Enzo, Farmingdale, NY) as per the manufacturers instructions.
5.6 Adoptive transfer of BM-derived IMC
CD45.1+ BM cells were cultured for 5 days with G-CSF (100 ng/ml), GM-CSF
(250 U/ml) and IL-13 (80 ng/ml) (Preprotech, Rocky Hill, NJ). MO-IMC were cell-
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sorted as described above and injected into sham Min or ETBF-colonized tumor-
bearing Min mice. Cells were recovered from enzymatically digested colon tumors
using FACS according to CD45.1, CD11b, Ly6C and Ly6G expression (Figure 6.9).
5.7 Taqman-based PCR array
Expression of 48 target genes by FACS-sorted myeloid populations were measured
using Taqman technology-based custom-designed PCR array plates or individual as-
says following the manufacturers instructions (Life Technologies). Expression of the
genes of interest was normalized to Gapdh expression. Results were expressed as ∆Ct
or ∆∆Ct (RQ, relative expression).
5.8 Immunohistochemistry
Serial FFPE tissue sections were deparaffinized and antigens retrieved by incu-
bation in citrate buffer. Slides were stained with anti-iNOS (N-20, sc-651, Santa
Cruz Biotechnology, Dallas, TX) or anti-arginase 1 (LS-B4789, LifeSpan BioSciences,
Seattle, WA). Poly-HRP conjugated anti-rabbit IgG (PV6119, Leica) was used as
secondary. Sections were analyzed on an EcliPSE E800 microscope (Nikon Corpora-
tion).
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5.9 Cytospin
MO- and PMN-IMC were cell-sorted as described above, fixed in 4% paraformalde-
hyde and annealed to slides via cytospin (800 rpm for 3 minutes). Slides were subse-
quently stained with Wright-Giemsa dye to visualize cells. Images were captured as
described above.
5.10 Statistical analysis
Data were analyzed using the Student t, ratio-paired t, Mann-Whitney U or chi
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Figure 6.1: ETBF Min mouse colons
A, ETBF-triggered tumorigenesis is prominent in distal colons of Min mice.
B, Colon tumor counts from chimeric Min mice reconstituted with bone marrow from
wildtype (C57BL/6) or Min donors. Tumor numbers were assessed at 12 weeks after
inoculation with ETBF. Representative image and graph of n=2 or more independent
experiments.
Figure 6.2: Gene expression analysis in ETBF tumor-infiltrating myeloid
cells
MΦ and MO-IMC were cell-sorted from 3 month ETBF Min colon tumors as
CD11bhiGR1-MHC+F4/80+ and CD11bhiGR1loMHCloF4/80-, respectively. Bars rep-
resent fold increase of gene expression (RQ) in MΦ compared to MO-MDSC. RQ
greater than 1, genes are overexpressed in tumor-associated macrophages; RQ less
than 1, genes are overexpressed in MO-IMC. Genes characterized by RQ greater than
2 and RQ less than 0.5 are highlighted above and below the graph. Red boxes indicate
genes characteristic of differentiated MΦ; green boxes indicate genes characteristic of
MO-MDSC. Representative graph of n=2 independent experiments.
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Figure 6.3: Gene expression array in PMN-IMC sorted from colon tumors
or spleen of 3 month ETBF Min mice
Bars represent fold increase of gene expression (RQ) in IMC sorted from tumors com-
pared to those sorted from spleen. RQ greater than 1 when genes are overexpressed in
tumor IMC; RQ less than 1 when genes are overexpressed in spleen. Genes character-
ized by RQ greater than 2 are highlighted. Representative graph of n=2 independent
experiments.
Figure 6.4: Gene expression array intratumoral MO-MDSC to PMN-IMC
sorted from colon tumors or spleen of 3 month ETBF Min mice
Same as in Figure 6.3. Representative graph of n=2 independent experiments.
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Figure 6.5: Myeloid cell populations (CD11b+GR1hi and CD11b+GR1neg)
cell-sorted from colon tumors for IL-17 qPCR were not contaminated by
T cells
Plots represent pre-sort CD3 and CD4 staining in CD11b+GR1hi, CD11b+GR1neg and
CD11b- gates used for cell sorting and subsequent Il17a mRNA detection in myeloid
cells associated with colon tumors, blood or spleen of 3 month ETBF-colonized Min
mice. Representative staining of n=2 independent samples from one cell sorting
experiment.
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Figure 6.6: Tumor-infiltrating MDSC express Il17a gene in colon tumors
A, PMN-IMC and MO-MDSC or MO-IMC were sorted from tumors, spleen or blood
of 3 month ETBF-colonized Min mice. RNA extracted from each cell subset was
assessed by qPCR for Il17a gene expression. Mean SEM is shown. Ct values were
normalized with CtGapdh (∆Ct=Ct-CtGapdh) and bars represent 2-∆Ct. Aggregate
data of n=2 independent experiments.
B, Myeloid and lymphoid populations were cell-sorted from wildtype or Min distal
colon lamina propria at day 7 post-ETBF colonization and assessed for Il17a, Rorc,
Irf4 and Il23r expression by qPCR. Bars represent fold increased (RQ) between
Min and wild type cell populations, RQ=2-∆∆Ct. Representative staining of n=2
independent samples from one cell sorting experiment.
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Figure 6.7: Confirmation of Nos2 gene expression by detection of nitric
oxide in culture supernatant of rIL-17-conditioned purified MO-MDSC
MO-MDSC cell-sorted from colon tumors or MO-IMC sorted from spleen in ETBF
Min mice were incubated overnight with IL-17 (10 ng/ml) in presence or absence
of LPS (100ng/ml). Nitric oxide (NO) was measured in culture supernatants using
a colorimetric assay. Lines represent geometric mean. Aggregate data from n=3-4
independent experiments.
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Figure 6.8: Stool culture of oncogenic bacteria to confirm colonization
Fresh stool samples were collected 7 days after inoculation with F. nucleatum, pks+
E. coli, E. coli ∆pks, ETBF or NTBF. Samples were homogenized in PBS, serially
diluted and cultured on Brucella (F. nucleatum), BHI (ETBF, NTBF) or MacConkey
(E. coli) agar under optimal anaerobic or aerobic conditions. Colony forming units
were manually counted within 24-48h of culturing.
82
CHAPTER 6. SUPPLEMENTAL FIGURES
Figure 6.9: Gating strategy for the recovery of adoptively-transferred in
vitro derived BM-MDSC
A, CD45.1+ bone marrow cells were harvested and MDSC were derived in vitro by
culture with G-CSF, GM-CSF and IL-13 for 5 days. MO-MDSC were cell-sorted and
adoptively transferred to Min recipients previously infected with ETBF (ETBF 11
weeks) via tail-vein injection.
B, Colon tumors were harvested 1 week later (ETBF 12 weeks) and CD45.1+ were
recovered and sorted by FACS for RNA extraction and Arg1/Nos2 qPCR analysis.
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Figure 6.10: CXCR2 is strongly expressed on ETBF tumor-associated
PMN-MDSC, while in the knockout staining is nullified
A, CXCR2 expression in CD11+ myeloid subsets harvested from the distal colon of
12-week ETBF colonized Min mice.
B, Comparison of CXCR2 expression by flow cytometry on myeloid subsets in 4-week
ETBF colonized WT versus CXCR2-/- mice.
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Figure 6.11: Expression of inflammatory cytokine receptors by colonic
MDSC
Expression of CX3CR1, CXCR2, CCR2 and CCR6 by CD11+ myeloid subsets in the
distal colon of 12-week ETBF-colonized Min mice.
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Date of birth: 26th August 1985
Place of birth: Boston, USA
6.2 Education
2010–2016 Immunology Graduate Program, Ph.D.
Johns Hopkins University, Baltimore, USA
2004–2010 Medical School, Dr. med. univ.
Medical University of Vienna, Vienna, Austria
2003 Reifeprüfung with distinction
‘Vienna Bilingual School’ Draschestraße, Vienna, Austria
6.3 PhD Thesis




Mentors Dr. Franck Housseau, Dr. Cynthia Sears, Dr. Drew Pardoll
Institute The Sidney Kimmel Comprehensive Cancer Research Center at Johns
Hopkins
Description Results Identified a myeloid immune signature characterized by the
specific accumulation of protumoral monocytic myeloid-derived suppressor
cells (MDSC) in a murine model of spontaneous carcinogenesis induced by
Enterotoxigenic Bacteroides fragilis (ETBF).
Significance First, inhibition of MDSC trafficking to the colon can abrogate
tumorigenesis and may represent a novel immunotherapy. Second, evidence
of a malignant myeloid immune signature in patients with ETBF infection
may allow for identification of those at risk of developing colorectal cancer.
Skills
• Broad knowledge of cancer immunotherapy
• Management of collaborative research projects
• Experimental design and statistical data analysis
• Characterization of suppressive tumor microenvironments
• Colony management of conditional transgenic mice with complex breed-
ing schemes
• Primary culture of tumor infiltrating lymphocytes and myeloid cells
• Multiparameter flow cytometry and cell sorting
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• Extraction, isolation and quantification of DNA & RNA
6.4 Publications
6.4.1 Scientific Articles
Oct 2015 Thiele Orberg E, Fan H, Tam A, Dejea C, Fathi P, Destefano-Shields C,
Wu S, Wu X, Chung L, Finard, B, Ganguly S, Fu J, Pardoll DM, Sears CL,
F Housseau. “The myeloid immune signature of Enterotoxigenic Bacteroides
fragilis-induced murine colon tumorigenesis.” Mucosal Immunology, in press.
Dec 2013 Llosa NJ, Geis AL, Thiele Orberg E, Housseau F. “Interleukin-17 and
type 17 helper T cells in cancer management and research.” ImmunoTargets
and Therapy, 2014(3):39-54.
Sep 2009 Thiele Orberg E, Asklin J, Wizel B, von Gabain A. “Impact of Immuniza-
tion Routes on Adjuvant-Induced T-Cell Immunity to Model Pathogen-Derived
Antigens.” Med. Univ. Vienna Dipl.-Arb., 2009.
6.4.2 Presentations and Posters
Jan 2016 Thiele Orberg E, Chung L, Fan H, Tam A, Wu S, Wu X, Ganguly S,
Fathi P, Dejea C, Pardoll DM, Sears CL, Housseau F. “The myeloid immune
signature of Enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis.”
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Keystone Symposium on Cancer Immunotherapy: Immunity and Immunosup-
pression Meet Targeted Therapies, Vancouver, Canada. Oral short talk and
poster.
Sep 2015 Thiele Orberg E, Fan H, Tam A, Wu S, Wu X, Ganguly S, Pardoll DM,
Sears CL, Housseau F. “The myeloid immune signature of Enterotoxigenic Bac-
teroides fragilis-induced colon tumorigenesis.” 18th ECCO – 40th ESMO Eu-
ropean Cancer Congress, Vienna, Austria. Oral short talk.
Mar 2014 Thiele Orberg E, Fan H, Wick E, Wu S, Pardoll DM, Sears CL, Housseau
F. “Immature myeloid cells as a link between inflammation and tumorigenesis
in bacterial colitis-associated carcinogenesis.” Keystone Symposium on Immune
Evolution in Cancer, Whistler, Canada. Oral short talk and poster.
Feb 2013 Thiele Orberg E, Sears CL, Wick E, Pardoll DM, Housseau F. “Hif-1α
and the regulation of pro-tumoral function of MDSC in colitis-induced colon
cancer.” Keystone Symposium on Myeloid Cells: Regulation and Inflammation,





Jan–Mar 2010 Visiting student
Karolinska Institutet, Stockholm, Sweden
Mentorship Dr. Birgitta Henriques Normark, Dr. Staffan Normark
Institute Swedish Institute for Infectious Disease Control
Description Involved in a project analyzing Pneumoccocus patient isolates
matched with clinical data to identify novel virulence factors.
Skills Culture of Streptococcus pneumoniae from clinical samples, DNA isola-
tion, amplification and multilocus sequence typing.
Feb–Nov 2008 Diploma thesis student
Intercell (Valneva), Vienna, Austria
Title Impact of Immunization Routes on Adjuvant-Induced T-Cell Immunity
to Model Pathogen-Derived Antigens
Mentorship Dr. Johanna Asklin, Dr. Benjamin Wizel, Dr. Alexander von
Gabain
Description Evaluation of the impact of different routes of immunization on
protective T-cell immunity. Immunized mice (intranasal, intraperitoneal,
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oral or subcutaneous) with antigens from a mucosal pathogen, Helicobac-
ter pylori, and from a systemic pathogen, Borrelia burgdorferi, together
with Intercell’s type 1 immunity-stimulating adjuvant IC31. Immuniza-
tion route and administration of IC31 were major determinants for the
induction of CD4+ T-cells and protection.
Skills Independent experimental work employing ELISPOT and ELISA to
quantify T-cell responses. Murine immunization and bacterial challenge
studies. Expertise in microbiology of Borrelia burgdorferi and Helicobac-
ter pylori. Extensively involved in initial lab setup.
6.5.2 Clinical Experience
Oct–Dec 2009 Erasmus exchange student
Université de Strasbourg, Faculté de Médicine, Straßburg, France
Rotations in gynacology, neurology and pediatrics.
Aug 2009 Elective rotation student
University of Illinois at Chicago, Division of Transplant Surgery, Chicago, USA
Elective rotation in surgery (transplantation).
July 2009 Medical student clerkship
Allgemeines Krankenhaus der Stadt Vienna, Vienna, Austria
Rotation in internal medicine (emergency medicine).
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Feb 2009 Medical student clerkship
Landeskrankenhaus Klagenfurt, Klagenfurt, Austria
Clerkship in pathology.
Aug 2007 Medical student clerkship
Allgemeines Krankenhaus der Stadt Vienna, Vienna, Austria
Rotation in internal medicine (bone marrow transplantation).
July 2007 Medical student clerkship
Unfallkrankenhaus Linz, Linz, Austria
Clerkship in primary care.
July 2006 Medical student clerkship
Sozialmedizinisches Zentrum Ost der Stadt Vienna, Vienna, Austria
Rotation in internal medicine (oncology).
Feb 2006 Medical student clerkship
Sozialmedizinisches Zentrum Ost der Stadt Vienna, Vienna, Austria





Jan 2015 Teaching assistant
Johns Hopkins School of Medicine, Baltimore, USA
Course Genes to Society: Immunology
Course director Dr. Jonathan Schneck
Description Intensive immunology course designed for medical students. In
afternoon small groups, students presented and discussed problem sets.
Skills Small group leader.
Feb–May 2012–2015 Teaching assistant
Johns Hopkins School of Medicine, Baltimore, USA
Course Graduate Immunology
Course director Dr. Scheherazade Sadegh-Nasseri (2012–2014), Dr. Mark
Soloski (2015)
Description Semester-long advanced immunology course consisting of lectures
and seminars. The seminars were designed to promote learning of class
topics by discussing original articles relevant to the week’s lectures.
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Skills Small group leader, preparation and presentation of class materials, con-
ducting journal club discussions as well as writing and grading of midterm
and final exams.
Oct 2013–2014 Teaching assistant
Johns Hopkins School of Medicine, Baltimore, USA
Course Scientific Foundations of Medicine: Cell Physiology
Course director Dr. Erika Matunis
Description Intensive physiology course designed for medical students. Course
objectives included fundamentals in physiology as well as experimental
methods that have enabled the advancement of medical knowledge.
Skills Small group leader.
6.6.2 Undergraduate Teaching
Aug–Nov 2015 Instructor
Johns Hopkins University, Baltimore, USA
Course Hopkins Engineering Applications & Research Teaching Tutorials: Im-
munoengineering




Description Development of a course on ‘Immunoengineering’, a nascent field
marrying medicine, immunology and engineering. In this three part course,
basics in immunology were introduced first, followed by applications in
vaccine technology as well as cancer immunology. This course was well




• Drafting accurate learning objectives
• Preparation of lectures, both traditional format and online (‘flipped
classroom’)
• Rational choice of teaching methods and assessment modalities
• Moderation of ‘active learning’ activities
Jan 2009 Teaching assistant
Medical University of Vienna, Vienna, Austria
Course Krankheit, Manifestation und Wahrnehmung, Allgemeine Arzneimit-
teltherapie
Course director Dr. Alexander Hirschl
Description The laboratory practice in microbiology teaches medical students
about laboratory practices for handling and diagnostics of pathogens.
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Skills Responsible for introducing students to the concept of handling, cultur-




July 2015 Teaching as Research Fellows Program
Johns Hopkins University, Baltimore, USA
Fellowship awarded to instructors to promote scientific methods in instruction
and evaluate in-class research projects regarding learning success.
2013–2015 Preparing Future Faculty Certificate Program
Johns Hopkins University, Baltimore, USA
The Preparing Future Faculty Program (PFF) recruits doctoral students pur-
suing academic careers. PFF fellows are trained in the basics of pedagogics and





2013 & 2015 Graduate Student Association Travel Award
The Johns Hopkins School of Medicine
2013 Best Poster Award
The 12th Annual Immunology Training Program Retreat
2009 Diploma thesis defense with distinction
Medical University of Vienna
2005-2008 Baxter Scholarship
The Baxter International Foundation
6.8 Leadership Skills
2012–2014 Student group president
The Hopkins Marathon TeamBaltimore, USA
Description President and captain of the Hopkins Marathon Team, a university-
wide student organization dedicated to promoting health and fitness on
campus through long distance running.
Skills
• Homepage design
• Author of a weekly newsletter reaching over 400 campus subscribers
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• Liasing with various student governing bodies on an all Johns Hopkins
campus
• Writing of grant applications and lobbying for funds
• Editor of various recruitment and advertising campaigns (Highlight:
Ads on Johns Hopkins shuttle busses)
• Coaching of marathon training groups
2012, 2015 Student coordinator
Johns Hopkins Immunology ForumBaltimore, USA
Responsible for inviting and hosting prominent reseachers to present at the
Immunology Forum, a weekly seminar on recent advances in immunology.
2012–2014 Student representative
Johns Hopkins School of Medicine Graduate Student AssociationBaltimore,
USA
Representative of the of the Immunology Graduate Program student body to
the Graduate Student Association
2012 Recruitment coordinator
Johns Hopkins Immunology Graduate ProgramBaltimore, USA
Reponsible for organizing recruitment activities for students applying to the
Immunology Graduate Program.
Updated on May 26, 2016.
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